Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond

Jenny Garmendia; Claudia De Sanctis; Viswanath Das; Narendran Annadurai; Marián Hajduch; Juan De Sanctis

doi:10.2174/1570159X22666231017141636

Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond

作者: Garmendia J.¹, De Sanctis C.¹, Das V.¹, Annadurai N.¹, Hajduch M.¹, De Sanctis J.¹
隶属关系:
1. Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University
期: 卷 22, 编号 6 (2024)
页面: 1080-1109
栏目: Neurology
URL: https://rjpbr.com/1570-159X/article/view/644809
DOI: https://doi.org/10.2174/1570159X22666231017141636
ID: 644809

如何引用文章

全文:

详细
作者简介
参考
补充文件
统计

详细

Neurodegenerative disease (ND) incidence has recently increased due to improved life expectancy. Alzheimer's (AD) or Parkinson's disease (PD) are the most prevalent NDs. Both diseases are poly genetic, multifactorial and heterogenous. Preventive medicine, a healthy diet, exercise, and controlling comorbidities may delay the onset. After the diseases are diagnosed, therapy is needed to slow progression. Recent studies show that local, peripheral and age-related inflammation accelerates NDs' onset and progression. Patients with autoimmune disorders like inflammatory bowel disease (IBD) could be at higher risk of developing AD or PD. However, no increase in ND incidence has been reported if the patients are adequately diagnosed and treated. Autoantibodies against abnormal tau, β amyloid and α- synuclein have been encountered in AD and PD and may be protective. This discovery led to the proposal of immune-based therapies for AD and PD involving monoclonal antibodies, immunization/vaccines, pro-inflammatory cytokine inhibition and anti-inflammatory cytokine addition. All the different approaches have been analysed here. Future perspectives on new therapeutic strategies for both disorders are concisely examined.

关键词

Neurodegenerative diseases (NDs), Alzheimer's disease (AD), Parkinson's disease (PD), β-amyloid, tau, α-synuclein, neurodegeneration, neuroinflammation, autoimmunity, therapy, vaccines.

参考

Price, D.L.; Sisodia, S.S.; Borchelt, D.R. Genetic neurodegenerative diseases: the human illness and transgenic models. Science, 1998, 282(5391), 1079-1083. doi: 10.1126/science.282.5391.1079 PMID: 9804539
MacDonald, M. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntingtons disease chromosomes. Cell, 1993, 72(6), 971-983. doi: 10.1016/0092-8674(93)90585-E PMID: 8458085
Akçimen, F.; Lopez, E.R.; Landers, J.E.; Nath, A.; Chiò, A.; Chia, R.; Traynor, B.J. Amyotrophic lateral sclerosis: Translating genetic discoveries into therapies. Nat. Rev. Genet., 2023, 24(9), 642-658. doi: 10.1038/s41576-023-00592-y PMID: 37024676
Papiri, G.; DAndreamatteo, G.; Cacchiò, G.; Alia, S.; Silvestrini, M.; Paci, C.; Luzzi, S.; Vignini, A. Multiple sclerosis: Inflammatory and neuroglial aspects. Curr. Issues Mol. Biol., 2023, 45(2), 1443-1470. doi: 10.3390/cimb45020094 PMID: 36826039
Klotz, L.; Antel, J.; Kuhlmann, T. Inflammation in multiple sclerosis: Consequences for remyelination and disease progression. Nat. Rev. Neurol., 2023, 19(5), 305-320. doi: 10.1038/s41582-023-00801-6 PMID: 37059811
Balcerac, A.; Louapre, C. Genetics and familial distribution of multiple sclerosis: A review. Rev. Neurol., 2022, 178(6), 512-520. doi: 10.1016/j.neurol.2021.11.009 PMID: 35148907
Breijyeh, Z.; Karaman, R. Comprehensive review on Alzheimers disease: Causes and treatment. Molecules, 2020, 25(24), 5789. doi: 10.3390/molecules25245789 PMID: 33302541
Rizek, P.; Kumar, N.; Jog, M.S. An update on the diagnosis and treatment of Parkinson disease. CMAJ, 2016, 188(16), 1157-1165. doi: 10.1503/cmaj.151179 PMID: 27221269
Aborode, A.T.; Pustake, M.; Awuah, W.A.; Alwerdani, M.; Shah, P.; Yarlagadda, R.; Ahmad, S.; Silva, C.I.F.; Chandra, A.; Nansubuga, E.P.; Abdul-Rahman, T.; Mehta, A.; Ali, O.; Amaka, S.O.; Zuñiga, Y.M.H.; Shkodina, A.D.; Inya, O.C.; Shen, B.; Alexiou, A. Targeting oxidative stress mechanisms to treat Alzheimers and Parkinsons disease: A critical review. Oxid. Med. Cell. Longev., 2022, 2022, 1-9. doi: 10.1155/2022/7934442 PMID: 35958022
Gorlé, N.; Van Cauwenberghe, C.; Libert, C.; Vandenbroucke, R.E. The effect of aging on brain barriers and the consequences for Alzheimers disease development. Mamm. Genome, 2016, 27(7-8), 407-420. doi: 10.1007/s00335-016-9637-8 PMID: 27143113
Dai, M.H.; Zheng, H.; Zeng, L.D.; Zhang, Y. The genes associated with early-onset Alzheimers disease. Oncotarget, 2018, 9(19), 15132-15143. doi: 10.18632/oncotarget.23738 PMID: 29599933
Sumirtanurdin, R.; Thalib, A.Y.; Cantona, K.; Abdulah, R. Effect of genetic polymorphisms on Alzheimers disease treatment outcomes: An update. Clin. Interv. Aging, 2019, 14, 631-642. doi: 10.2147/CIA.S200109 PMID: 30992661
Sarnowski, C.; Ghanbari, M.; Bis, J.C.; Logue, M.; Fornage, M.; Mishra, A.; Ahmad, S.; Beiser, A.S.; Boerwinkle, E.; Bouteloup, V.; Chouraki, V.; Cupples, L.A.; Damotte, V.; DeCarli, C.S.; DeStefano, A.L.; Djoussé, L.; Fohner, A.E.; Franz, C.E.; Kautz, T.F.; Lambert, J.C.; Lyons, M.J.; Mosley, T.H.; Mukamal, K.J.; Pase, M.P.; Portilla Fernandez, E.C.; Rissman, R.A.; Satizabal, C.L.; Vasan, R.S.; Yaqub, A.; Debette, S.; Dufouil, C.; Launer, L.J.; Kremen, W.S.; Longstreth, W.T.; Ikram, M.A.; Seshadri, S. Meta-analysis of genome-wide association studies identifies ancestry-specific associations underlying circulating total tau levels. Commun. Biol., 2022, 5(1), 336. doi: 10.1038/s42003-022-03287-y PMID: 35396452
Su, F.; Bai, F.; Zhang, Z. Inflammatory cytokines and Alzheimers disease: A review from the perspective of genetic polymorphisms. Neurosci. Bull., 2016, 32(5), 469-480. doi: 10.1007/s12264-016-0055-4 PMID: 27568024
Ulhaq, Z.S.; Garcia, C.P. Inflammation-related gene polymorphisms associated with Parkinsons disease: An updated meta-analysis. Egypt. J. Med. Hum. Genet., 2020, 21(1), 14. doi: 10.1186/s43042-020-00056-6
Li, X.; Zhang, D.F.; Bi, R.; Tan, L.W.; Chen, X.; Xu, M.; Yao, Y.G. Convergent transcriptomic and genomic evidence supporting a dysregulation of CXCL16 and CCL5 in Alzheimers disease. Alzheimers Res. Ther., 2023, 15(1), 17. doi: 10.1186/s13195-022-01159-5 PMID: 36670424
Pedersen, C.C.; Lange, J.; Førland, M.G.G.; Macleod, A.D.; Alves, G.; Maple-Grødem, J. A systematic review of associations between common SNCA variants and clinical heterogeneity in Parkinsons disease. NPJ Parkinsons Dis., 2021, 7(1), 54. doi: 10.1038/s41531-021-00196-5 PMID: 34210990
Hollenbach, J.A.; Norman, P.J.; Creary, L.E.; Damotte, V.; Montero-Martin, G.; Caillier, S.; Anderson, K.M.; Misra, M.K.; Nemat-Gorgani, N.; Osoegawa, K.; Santaniello, A.; Renschen, A.; Marin, W.M.; Dandekar, R.; Parham, P.; Tanner, C.M.; Hauser, S.L.; Fernandez-Viña, M.; Oksenberg, J.R. A specific amino acid motif of HLA-DRB1 mediates risk and interacts with smoking history in Parkinsons disease. Proc. Natl. Acad. Sci., 2019, 116(15), 7419-7424. doi: 10.1073/pnas.1821778116 PMID: 30910980
Yu, E.; Ambati, A.; Andersen, M.S.; Krohn, L.; Estiar, M.A.; Saini, P.; Senkevich, K.; Sosero, Y.L.; Sreelatha, A.A.K.; Ruskey, J.A.; Asayesh, F.; Spiegelman, D.; Toft, M.; Viken, M.K.; Sharma, M.; Blauwendraat, C.; Pihlstrøm, L.; Mignot, E.; Gan-Or, Z. Fine mapping of the HLA locus in Parkinsons disease in Europeans. NPJ Parkinsons Dis., 2021, 7(1), 84. doi: 10.1038/s41531-021-00231-5 PMID: 34548497
Harms, A.S.; Ferreira, S.A.; Romero-Ramos, M. Periphery and brain, innate and adaptive immunity in Parkinsons disease. Acta Neuropathol., 2021, 141(4), 527-545. doi: 10.1007/s00401-021-02268-5 PMID: 33555429
Yi, M.; Li, J.; Jian, S.; Li, B.; Huang, Z.; Shu, L.; Zhang, Y. Quantitative and causal analysis for inflammatory genes and the risk of Parkinsons disease. Front. Immunol., 2023, 14, 1119315. doi: 10.3389/fimmu.2023.1119315 PMID: 36926335
Abbott, N.J.; Patabendige, A.A.K.; Dolman, D.E.M.; Yusof, S.R.; Begley, D.J. Structure and function of the bloodbrain barrier. Neurobiol. Dis., 2010, 37(1), 13-25. doi: 10.1016/j.nbd.2009.07.030 PMID: 19664713
Labzin, L.I.; Heneka, M.T.; Latz, E. Innate immunity and neurodegeneration. Annu. Rev. Med., 2018, 69(1), 437-449. doi: 10.1146/annurev-med-050715-104343 PMID: 29106805
Huang, X.; Hussain, B.; Chang, J. Peripheral inflammation and bloodbrain barrier disruption: Effects and mechanisms. CNS Neurosci. Ther., 2021, 27(1), 36-47. doi: 10.1111/cns.13569 PMID: 33381913
Wilhelm, I.; Nyúl-Tóth, Á.; Suciu, M.; Hermenean, A.; Krizbai, I.A. Heterogeneity of the blood-brain barrier. Tissue Barriers, 2016, 4(1), e1143544. doi: 10.1080/21688370.2016.1143544 PMID: 27141424
Mayne, K.; White, J.A.; McMurran, C.E.; Rivera, F.J.; de la Fuente, A.G. Aging and neurodegenerative disease: Is the adaptive immune system a friend or foe? Front. Aging Neurosci., 2020, 12, 572090. doi: 10.3389/fnagi.2020.572090 PMID: 33173502
Glass, C.K.; Saijo, K.; Winner, B.; Marchetto, M.C.; Gage, F.H. Mechanisms underlying inflammation in neurodegeneration. Cell, 2010, 140(6), 918-934. doi: 10.1016/j.cell.2010.02.016 PMID: 20303880
Stephenson, J.; Nutma, E.; van der Valk, P.; Amor, S. Inflammation in CNS neurodegenerative diseases. Immunology, 2018, 154(2), 204-219. doi: 10.1111/imm.12922 PMID: 29513402
Fathi, M.; Vakili, K.; Yaghoobpoor, S.; Qadirifard, M.S.; Kosari, M.; Naghsh, N.; Asgari taei, A.; Klegeris, A.; Dehghani, M.; Bahrami, A.; Taheri, H.; Mohamadkhani, A.; Hajibeygi, R.; Rezaei Tavirani, M.; Sayehmiri, F. Pre-clinical studies identifying molecular pathways of neuroinflammation in Parkinsons disease: A systematic review. Front. Aging Neurosci., 2022, 14, 855776. doi: 10.3389/fnagi.2022.855776 PMID: 35912090
Gorecki, A.M.; Anyaegbu, C.C.; Anderton, R.S. TLR2 and TLR4 in Parkinsons disease pathogenesis: The environment takes a toll on the gut. Transl. Neurodegener., 2021, 10(1), 47. doi: 10.1186/s40035-021-00271-0 PMID: 34814947
Bellucci, A.; Bubacco, L.; Longhena, F.; Parrella, E.; Faustini, G.; Porrini, V.; Bono, F.; Missale, C.; Pizzi, M. Nuclear Factor-κB dysregulation and α-synuclein pathology: Critical interplay in the pathogenesis of Parkinsons disease. Front. Aging Neurosci., 2020, 12, 68. doi: 10.3389/fnagi.2020.00068 PMID: 32265684
Juranek, J.; Mukherjee, K.; Kordas, B.; Załęcki, M.; Korytko, A.; Zglejc-Waszak, K.; Szuszkiewicz, J.; Banach, M. Role of RAGE in the pathogenesis of neurological disorders. Neurosci. Bull., 2022, 38(10), 1248-1262. doi: 10.1007/s12264-022-00878-x PMID: 35729453
Spulber, S.; Bartfai, T.; Schultzberg, M. IL-1/IL-1ra balance in the brain revisited: Evidence from transgenic mouse models. Brain Behav. Immun., 2009, 23(5), 573-579. doi: 10.1016/j.bbi.2009.02.015 PMID: 19258032
Bai, H.; Zhang, Q. Activation of NLRP3 inflammasome and onset of Alzheimers disease. Front. Immunol., 2021, 12, 701282. doi: 10.3389/fimmu.2021.701282 PMID: 34381452
Martin-Ruiz, C.; Williams-Gray, C.H.; Yarnall, A.J.; Boucher, J.J.; Lawson, R.A.; Wijeyekoon, R.S.; Barker, R.A.; Kolenda, C.; Parker, C.; Burn, D.J.; Von Zglinicki, T.; Saretzki, G. Senescence and inflammatory markers for predicting clinical progression in Parkinsons disease: The ICICLE-PD Study. J. Parkinsons Dis., 2020, 10(1), 193-206. doi: 10.3233/JPD-191724 PMID: 31868677
Lara, P.C.; Macías-Verde, D.; Burgos-Burgos, J. Age-induced NLRP3 inflammasome over-activation increases lethality of SARS-CoV-2 pneumonia in elderly patients. Aging Dis., 2020, 11(4), 756-762. doi: 10.14336/AD.2020.0601 PMID: 32765942
Stout-Delgado, H.W.; Vaughan, S.E.; Shirali, A.C.; Jaramillo, R.J.; Harrod, K.S. Impaired NLRP3 inflammasome function in elderly mice during influenza infection is rescued by treatment with nigericin. J. Immunol., 2012, 188(6), 2815-2824. doi: 10.4049/jimmunol.1103051 PMID: 22327078
Nagatsu, T.; Mogi, M.; Ichinose, H.; Togari, A. Changes in cytokines and neurotrophins in Parkinsons disease. J. Neural Transm. Suppl., 2000, (60), 277-290. doi: 10.1007/978-3-7091-6301-6_19 PMID: 11205147
Zhang, P.; Shao, X.Y.; Qi, G.J.; Chen, Q.; Bu, L.L.; Chen, L.J.; Shi, J.; Ming, J.; Tian, B. Cdk5-dependent activation of neuronal inflammasomes in Parkinsons disease. Mov. Disord., 2016, 31(3), 366-376. doi: 10.1002/mds.26488 PMID: 26853432
Kitazawa, M.; Cheng, D.; Tsukamoto, M.R.; Koike, M.A.; Wes, P.D.; Vasilevko, V.; Cribbs, D.H.; LaFerla, F.M. Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimers disease model. J. Immunol., 2011, 187(12), 6539-6549. doi: 10.4049/jimmunol.1100620 PMID: 22095718
Wang, W.; Nguyen, L.T.T.; Burlak, C.; Chegini, F.; Guo, F.; Chataway, T.; Ju, S.; Fisher, O.S.; Miller, D.W.; Datta, D.; Wu, F.; Wu, C.X.; Landeru, A.; Wells, J.A.; Cookson, M.R.; Boxer, M.B.; Thomas, C.J.; Gai, W.P.; Ringe, D.; Petsko, G.A.; Hoang, Q.Q. Caspase-1 causes truncation and aggregation of the Parkinsons disease-associated protein α-synuclein. Proc. Natl. Acad. Sci., 2016, 113(34), 9587-9592. doi: 10.1073/pnas.1610099113 PMID: 27482083
Hurelbrink, C.B.; Armstrong, R.J.E.; Luheshi, L.M.; Dunnett, S.B.; Rosser, A.E.; Barker, R.A. Death of dopaminergic neurons in vitro and in nigral grafts: Reevaluating the role of caspase activation. Exp. Neurol., 2001, 171(1), 46-58. doi: 10.1006/exnr.2001.7749 PMID: 11520120
Caputi, V.; Giron, M. Microbiome-gut-brain axis and toll-like receptors in Parkinsons disease. Int. J. Mol. Sci., 2018, 19(6), 1689. doi: 10.3390/ijms19061689 PMID: 29882798
Howe, A.M.; Burke, S.; OReilly, M.E.; McGillicuddy, F.C.; Costello, D.A. Palmitic acid and oleic acid differently modulate tlr2-mediated inflammatory responses in microglia and macrophages. Mol. Neurobiol., 2022, 59(4), 2348-2362. doi: 10.1007/s12035-022-02756-z PMID: 35079937
Minoretti, P.; Gazzaruso, C.; Vito, C.D.; Emanuele, E.; Bianchi, M.; Coen, E.; Reino, M.; Geroldi, D. Effect of the functional toll-like receptor 4 Asp299Gly polymorphism on susceptibility to late-onset Alzheimers disease. Neurosci. Lett., 2006, 391(3), 147-149. doi: 10.1016/j.neulet.2005.08.047 PMID: 16157451
Okun, E.; Griffioen, K.J.; Lathia, J.D.; Tang, S.C.; Mattson, M.P.; Arumugam, T.V. Toll-like receptors in neurodegeneration. Brain Res. Brain Res. Rev., 2009, 59(2), 278-292. doi: 10.1016/j.brainresrev.2008.09.001 PMID: 18822314
Liddelow, S.A.; Barres, B.A. Reactive Astrocytes: Production, Function, and Therapeutic Potential. Immunity, 2017, 46(6), 957-967. doi: 10.1016/j.immuni.2017.06.006 PMID: 28636962
Labib, D.; Wang, Z.; Prakash, P.; Zimmer, M.; Smith, M.D.; Frazel, P.W.; Barbar, L.; Sapar, M.L.; Calabresi, P.A.; Peng, J.; Liddelow, S.A.; Fossati, V. Proteomic Alterations and Novel Markers of Neurotoxic Reactive Astrocytes in Human Induced Pluripotent Stem Cell Models. Front. Mol. Neurosci., 2022, 15, 870085. doi: 10.3389/fnmol.2022.870085 PMID: 35592112
Zhao, Y.; Bhattacharjee, S.; Jones, B.M.; Hill, J.; Dua, P.; Lukiw, W.J. Regulation of neurotropic signaling by the inducible, NF-kB-sensitive miRNA-125b in Alzheimers disease (AD) and in primary human neuronal-glial (HNG) cells. Mol. Neurobiol., 2014, 50(1), 97-106. doi: 10.1007/s12035-013-8595-3 PMID: 24293102
Singh, S.; Singh, T.G. Role of Nuclear Factor Kappa B (NF-κB) signalling in neurodegenerative diseases: A mechanistic approach. Curr. Neuropharmacol., 2020, 18(10), 918-935. doi: 10.2174/1570159X18666200207120949 PMID: 32031074
Dou, F.; Chu, X.; Zhang, B.; Liang, L.; Lu, G.; Ding, J.; Chen, S. EriB targeted inhibition of microglia activity attenuates MPP+ induced DA neuron injury through the NF-κB signaling pathway. Mol. Brain, 2018, 11(1), 75. doi: 10.1186/s13041-018-0418-z PMID: 30563578
Rauf, A.; Badoni, H.; Abu-Izneid, T.; Olatunde, A.; Rahman, M.M.; Painuli, S.; Semwal, P.; Wilairatana, P.; Mubarak, M.S. Neuroinflammatory markers: Key indicators in the pathology of neurodegenerative diseases. Molecules, 2022, 27(10), 3194. doi: 10.3390/molecules27103194 PMID: 35630670
Huang, Y.; Erdmann, N.; Peng, H.; Zhao, Y.; Zheng, J. The role of TNF related apoptosis-inducing ligand in neurodegenerative diseases. Cell. Mol. Immunol., 2005, 2(2), 113-122. PMID: 16191417
Uberti, D.; Cantarella, G.; Facchetti, F.; Cafici, A.; Grasso, G.; Bernardini, R.; Memo, M. TRAIL is expressed in the brain cells of Alzheimers disease patients. Neuroreport, 2004, 15(4), 579-581.
Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G.M.; Cooper, N.R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B.L.; Finch, C.E.; Frautschy, S.; Griffin, W.S.; Hampel, H.; Hull, M.; Landreth, G.; Lue, L.; Mrak, R.; Mackenzie, I.R.; McGeer, P.L.; OBanion, M.K.; Pachter, J.; Pasinetti, G.; Plata-Salaman, C.; Rogers, J.; Rydel, R.; Shen, Y.; Streit, W.; Strohmeyer, R.; Tooyoma, I.; Van Muiswinkel, F.L.; Veerhuis, R.; Walker, D.; Webster, S.; Wegrzyniak, B.; Wenk, G.; Wyss-Coray, T. Inflammation and Alzheimers disease. Neurobiol. Aging, 2000, 21(3), 383-421. doi: 10.1016/S0197-4580(00)00124-X PMID: 10858586
Tarkowski, E.; Liljeroth, A.M.; Nilsson, Å.; Minthon, L.; Blennow, K. Decreased levels of intrathecal interleukin 1 receptor antagonist in Alzheimers disease. Dement. Geriatr. Cogn. Disord., 2001, 12(5), 314-317. doi: 10.1159/000051276 PMID: 11455132
He, P.; Zhong, Z.; Lindholm, K.; Berning, L.; Lee, W.; Lemere, C.; Staufenbiel, M.; Li, R.; Shen, Y. Deletion of tumor necrosis factor death receptor inhibits amyloid β generation and prevents learning and memory deficits in Alzheimers mice. J. Cell Biol., 2007, 178(5), 829-841. doi: 10.1083/jcb.200705042 PMID: 17724122
Hickman, S.E.; Allison, E.K.; El Khoury, J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimers disease mice. J. Neurosci., 2008, 28(33), 8354-8360. doi: 10.1523/JNEUROSCI.0616-08.2008 PMID: 18701698
Nutma, E.; van Gent, D.; Amor, S.; Peferoen, L.A.N. Astrocyte and oligodendrocyte cross-talk in the central nervous system. Cells, 2020, 9(3), 600. doi: 10.3390/cells9030600 PMID: 32138223
Santoro, A.; Spinelli, C.C.; Martucciello, S.; Nori, S.L.; Capunzo, M.; Puca, A.A.; Ciaglia, E. Innate immunity and cellular senescence: The good and the bad in the developmental and aged brain. J. Leukoc. Biol., 2018, 103(3), 509-524. doi: 10.1002/JLB.3MR0118-003R PMID: 29389023
Tan, Z.S.; Beiser, A.S.; Vasan, R.S.; Roubenoff, R.; Dinarello, C.A.; Harris, T.B.; Benjamin, E.J.; Au, R.; Kiel, D.P.; Wolf, P.A.; Seshadri, S. Inflammatory markers and the risk of Alzheimer disease: The Framingham Study. Neurology, 2007, 68(22), 1902-1908. doi: 10.1212/01.wnl.0000263217.36439.da PMID: 17536046
Burré, J.; Sharma, M.; Südhof, T.C. Cell biology and pathophysiology of α-synuclein. Cold Spring Harb. Perspect. Med., 2018, 8(3), a024091. doi: 10.1101/cshperspect.a024091 PMID: 28108534
Nakanishi, H. Microglial cathepsin B as a key driver of inflammatory brain diseases and brain aging. Neural Regen. Res., 2020, 15(1), 25-29. doi: 10.4103/1673-5374.264444 PMID: 31535638
Kim, C.; Ho, D.H.; Suk, J.E.; You, S.; Michael, S.; Kang, J.; Joong Lee, S.; Masliah, E.; Hwang, D.; Lee, H.J.; Lee, S.J. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun., 2013, 4(1), 1562. doi: 10.1038/ncomms2534 PMID: 23463005
Xie, Y.X.; Naseri, N.N.; Fels, J.; Kharel, P.; Na, Y.; Lane, D.; Burré, J.; Sharma, M. Lysosomal exocytosis releases pathogenic α-synuclein species from neurons in synucleinopathy models. Nat. Commun., 2022, 13(1), 4918. doi: 10.1038/s41467-022-32625-1 PMID: 35995799
Lashuel, H.A.; Overk, C.R.; Oueslati, A.; Masliah, E. The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci., 2013, 14(1), 38-48. doi: 10.1038/nrn3406 PMID: 23254192
Bendor, J.T.; Logan, T.P.; Edwards, R.H. The function of α-synuclein. Neuron, 2013, 79(6), 1044-1066. doi: 10.1016/j.neuron.2013.09.004 PMID: 24050397
Soraci, L.; Gambuzza, M.E.; Biscetti, L.; Laganà, P.; Lo Russo, C.; Buda, A.; Barresi, G.; Corsonello, A.; Lattanzio, F.; Lorello, G.; Filippelli, G.; Marino, S. Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinsons disease: Mechanisms and therapeutic implications. J. Neurol., 2023, 270(3), 1346-1360. doi: 10.1007/s00415-022-11491-3 PMID: 36460875
Volpicelli-Daley, L.; Brundin, P. Prion-like propagation of pathology in Parkinson disease. Handb. Clin. Neurol., 2018, 153, 321-335. doi: 10.1016/B978-0-444-63945-5.00017-9 PMID: 29887143
Noguchi-Shinohara, M.; Ono, K. The mechanisms of the roles of α-synuclein, amyloid-β, and tau protein in the lewy body diseases: pathogenesis, early detection, and therapeutics. Int. J. Mol. Sci., 2023, 24(12), 10215. doi: 10.3390/ijms241210215 PMID: 37373401
Schrag, A. Psychiatric aspects of Parkinsons disease. J. Neurol., 2004, 251(7), 795-804. doi: 10.1007/s00415-004-0483-3 PMID: 15258780
Subramanian, A.; Tamilanban, T.; Alsayari, A.; Ramachawolran, G.; Wong, L.S.; Sekar, M.; Gan, S.H.; Subramaniyan, V.; Chinni, S.V.; Izzati Mat Rani, N.N.; Suryadevara, N.; Wahab, S. Trilateral association of autophagy, mTOR and Alzheimers disease: Potential pathway in the development for Alzheimers disease therapy. Front. Pharmacol., 2022, 13, 1094351. doi: 10.3389/fphar.2022.1094351 PMID: 36618946
Kostiuchenko, O.; Lushnikova, I.; Kowalczyk, M.; Skibo, G. mTOR/α-ketoglutarate-mediated signaling pathways in the context of brain neurodegeneration and neuroprotection. BBA Adv., 2022, 2, 100066. doi: 10.1016/j.bbadva.2022.100066 PMID: 37082603
Blagov, A.V.; Grechko, A.V.; Nikiforov, N.G.; Borisov, E.E.; Sadykhov, N.K.; Orekhov, A.N. Role of impaired mitochondrial dynamics processes in the pathogenesis of Alzheimers disease. Int. J. Mol. Sci., 2022, 23(13), 6954. doi: 10.3390/ijms23136954 PMID: 35805958
Ikeda-Matsuo, Y.; Miyata, H.; Mizoguchi, T.; Ohama, E.; Naito, Y.; Uematsu, S.; Akira, S.; Sasaki, Y.; Tanabe, M. Microsomal prostaglandin E synthase-1 is a critical factor in dopaminergic neurodegeneration in Parkinsons disease. Neurobiol. Dis., 2019, 124, 81-92. doi: 10.1016/j.nbd.2018.11.004 PMID: 30423474
Mi, Y.; Qi, G.; Vitali, F.; Shang, Y.; Raikes, A.C.; Wang, T.; Jin, Y.; Brinton, R.D.; Gu, H.; Yin, F. Loss of fatty acid degradation by astrocytic mitochondria triggers neuroinflammation and neurodegeneration. Nat. Metab., 2023, 5(3), 445-465. doi: 10.1038/s42255-023-00756-4 PMID: 36959514
Kulminski, A.M.; Jain-Washburn, E.; Loiko, E.; Loika, Y.; Feng, F.; Culminskaya, I. Associations of the APOE ε2 and ε4 alleles and polygenic profiles comprising APOE-TOMM40-APOC1 variants with Alzheimers disease biomarkers. Aging, 2022, 14(24), 9782-9804. doi: 10.18632/aging.204384 PMID: 36399096
Mu, G.; Ren, C.; Zhang, Y.; Lu, B.; Feng, J.; Wu, D.; Xu, X.; Ou, C. Amelioration of central neurodegeneration by docosahexaenoic acid in trigeminal neuralgia rats through the regulation of central neuroinflammation. Int. Immunopharmacol., 2023, 114, 109544. doi: 10.1016/j.intimp.2022.109544 PMID: 36527885
Xie, A.; Ensink, E.; Li, P.; Gordevičius, J.; Marshall, L.L.; George, S.; Pospisilik, J.A.; Aho, V.T.E.; Houser, M.C.; Pereira, P.A.B.; Rudi, K.; Paulin, L.; Tansey, M.G.; Auvinen, P.; Brundin, P.; Brundin, L.; Labrie, V.; Scheperjans, F. Bacterial butyrate in parkinsons disease is linked to epigenetic changes and depressive symptoms. Mov. Disord., 2022, 37(8), 1644-1653. doi: 10.1002/mds.29128 PMID: 35723531
Verhaar, B.J.H.; Hendriksen, H.M.A.; de Leeuw, F.A.; Doorduijn, A.S.; van Leeuwenstijn, M.; Teunissen, C.E.; Barkhof, F.; Scheltens, P.; Kraaij, R.; van Duijn, C.M.; Nieuwdorp, M.; Muller, M.; van der Flier, W.M. Gut microbiota composition is related to ad pathology. Front. Immunol., 2022, 12, 794519. doi: 10.3389/fimmu.2021.794519 PMID: 35173707
Cammann, D.; Lu, Y.; Cummings, M.J.; Zhang, M.L.; Cue, J.M.; Do, J.; Ebersole, J.; Chen, X.; Oh, E.C.; Cummings, J.L.; Chen, J. Genetic correlations between Alzheimers disease and gut microbiome genera. Sci. Rep., 2023, 13(1), 5258. doi: 10.1038/s41598-023-31730-5 PMID: 37002253
Lang, Y.; Chu, F.; Shen, D.; Zhang, W.; Zheng, C.; Zhu, J.; Cui, L. Role of inflammasomes in neuroimmune and neurodegenerative diseases: A systematic review. Mediators Inflamm., 2018, 2018, 1-11. doi: 10.1155/2018/1549549 PMID: 29849483
Miao, J.; Ma, H.; Yang, Y.; Liao, Y.; Lin, C.; Zheng, J.; Yu, M.; Lan, J. Microglia in Alzheimers disease: Pathogenesis, mechanisms, and therapeutic potentials. Front. Aging Neurosci., 2023, 15, 1201982. doi: 10.3389/fnagi.2023.1201982 PMID: 37396657
Wes, P.D.; Holtman, I.R.; Boddeke, E.W.G.M.; Möller, T.; Eggen, B.J.L. Next generation transcriptomics and genomics elucidate biological complexity of microglia in health and disease. Glia, 2016, 64(2), 197-213. doi: 10.1002/glia.22866 PMID: 26040959
Holtman, I.R.; Raj, D.D.; Miller, J.A.; Schaafsma, W.; Yin, Z.; Brouwer, N.; Wes, P.D.; Möller, T.; Orre, M.; Kamphuis, W.; Hol, E.M.; Boddeke, E.W.G.M.; Eggen, B.J.L. Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: A co-expression meta-analysis. Acta Neuropathol. Commun., 2015, 3(1), 31. doi: 10.1186/s40478-015-0203-5 PMID: 26001565
Pan, J.; Ma, N.; Yu, B.; Zhang, W.; Wan, J. Transcriptomic profiling of microglia and astrocytes throughout aging. J. Neuroinflammation, 2020, 17(1), 97. doi: 10.1186/s12974-020-01774-9 PMID: 32238175
Spurrier, J.; Nicholson, L.; Fang, X.T.; Stoner, A.J.; Toyonaga, T.; Holden, D.; Siegert, T.R.; Laird, W.; Allnutt, M.A.; Chiasseu, M.; Brody, A.H.; Takahashi, H.; Nies, S.H.; Cañamás, A.P.; Sadasivam, P.; Lee, S.; Li, S.; Zhang, L.; Huang, Y.H.; Carson, R.E.; Cai, Z.; Strittmatter, S.M. Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q. Sci. Transl. Med., 2022, 14(647), eabi8593. doi: 10.1126/scitranslmed.abi8593 PMID: 35648810
Balog, B.M.; Sonti, A.; Zigmond, R.E. Neutrophil biology in injuries and diseases of the central and peripheral nervous systems. Prog. Neurobiol., 2023, 228, 102488. doi: 10.1016/j.pneurobio.2023.102488 PMID: 37355220
Aries, M.L.; Hensley-McBain, T. Neutrophils as a potential therapeutic target in Alzheimers disease. Front. Immunol., 2023, 14, 1123149. doi: 10.3389/fimmu.2023.1123149 PMID: 36936930
Harcha, P.A.; Garcés, P.; Arredondo, C.; Fernández, G.; Sáez, J.C.; van Zundert, B. Mast cell and astrocyte hemichannels and their role in alzheimers disease, ALS, and harmful stress conditions. Int. J. Mol. Sci., 2021, 22(4), 1924. doi: 10.3390/ijms22041924 PMID: 33672031
Wang, S.; van de Pavert, S.A. Innate lymphoid cells in the central nervous system. Front. Immunol., 2022, 13, 837250. doi: 10.3389/fimmu.2022.837250 PMID: 35185929
Brauning, A.; Rae, M.; Zhu, G.; Fulton, E.; Admasu, T.D.; Stolzing, A.; Sharma, A. Aging of the immune system: Focus on natural killer cells phenotype and functions. Cells, 2022, 11(6), 1017. doi: 10.3390/cells11061017 PMID: 35326467
Prager, I.; Watzl, C. Mechanisms of natural killer cell-mediated cellular cytotoxicity. J. Leukoc. Biol., 2019, 105(6), 1319-1329. doi: 10.1002/JLB.MR0718-269R PMID: 31107565
Menees, K.B.; Lee, J.K. New insights and implications of natural killer cells in parkinsons disease. J. Parkinsons Dis., 2022, 12(s1), S83-S92. doi: 10.3233/JPD-223212 PMID: 35570499
Zhang, L.; Zhang, Y.; Fan, D. Pathological role of natural killer cells in parkinsons disease: A systematic review. Front. Aging Neurosci., 2022, 14, 890816. doi: 10.3389/fnagi.2022.890816 PMID: 35663564
Muñiz-Castrillo, S.; Vogrig, A.; Honnorat, J. Associations between HLA and autoimmune neurological diseases with autoantibodies. Auto Immun. Highlights, 2020, 11(1), 2. doi: 10.1186/s13317-019-0124-6 PMID: 32127039
Boon, B.D.C.; Hoozemans, J.J.M.; Lopuhaä, B.; Eigenhuis, K.N.; Scheltens, P.; Kamphorst, W.; Rozemuller, A.J.M.; Bouwman, F.H. Neuroinflammation is increased in the parietal cortex of atypical Alzheimers disease. J. Neuroinflammation, 2018, 15(1), 170. doi: 10.1186/s12974-018-1180-y PMID: 29843759
Wang, Z.T.; Chen, S.D.; Xu, W.; Chen, K.L.; Wang, H.F.; Tan, C.C.; Cui, M.; Dong, Q.; Tan, L.; Yu, J.T. Genome-wide association study identifies CD1A associated with rate of increase in plasma neurofilament light in non-demented elders. Aging, 2019, 11(13), 4521-4535. doi: 10.18632/aging.102066 PMID: 31295725
Chew, H.; Solomon, V.A.; Fonteh, A.N. Involvement of lipids in Alzheimers disease pathology and potential therapies. Front. Physiol., 2020, 11, 598. doi: 10.3389/fphys.2020.00598 PMID: 32581851
Al-kuraishy, H.M.; Al-Gareeb, A.I.; Alexiou, A.; Papadakis, M.; Alsayegh, A.A.; Almohmadi, N.H.; Saad, H.M.; Batiha, G.E.S. Pros and cons for statins use and risk of Parkinsons disease: An updated perspective. Pharmacol. Res. Perspect., 2023, 11(2), e01063. doi: 10.1002/prp2.1063 PMID: 36811160
Sulzer, D.; Alcalay, R.N.; Garretti, F.; Cote, L.; Kanter, E.; Agin-Liebes, J.; Liong, C.; McMurtrey, C.; Hildebrand, W.H.; Mao, X.; Dawson, V.L.; Dawson, T.M.; Oseroff, C.; Pham, J.; Sidney, J.; Dillon, M.B.; Carpenter, C.; Weiskopf, D.; Phillips, E.; Mallal, S.; Peters, B.; Frazier, A.; Lindestam, A.C.S.; Sette, A. T cells from patients with Parkinsons disease recognize α-synuclein peptides. Nature, 2017, 546(7660), 656-661. doi: 10.1038/nature22815 PMID: 28636593
Williams, G.P.; Schonhoff, A.M.; Jurkuvenaite, A.; Gallups, N.J.; Standaert, D.G.; Harms, A.S. CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinsons disease. Brain, 2021, 144(7), 2047-2059. doi: 10.1093/brain/awab103 PMID: 33704423
Iba, M.; Kim, C.; Sallin, M.; Kwon, S.; Verma, A.; Overk, C.; Rissman, R.A.; Sen, R.; Sen, J.M.; Masliah, E. Neuroinflammation is associated with infiltration of T cells in Lewy body disease and α-synuclein transgenic models. J. Neuroinflammation, 2020, 17(1), 214. doi: 10.1186/s12974-020-01888-0 PMID: 32680537
Lyman, M.; Lloyd, D.G.; Ji, X.; Vizcaychipi, M.P.; Ma, D. Neuroinflammation: The role and consequences. Neurosci. Res., 2014, 79, 1-12. doi: 10.1016/j.neures.2013.10.004 PMID: 24144733
Carrasco, E.; Gómez de las Heras, M.M.; Gabandé-Rodríguez, E.; Desdín-Micó, G.; Aranda, J.F.; Mittelbrunn, M. The role of T cells in age-related diseases. Nat. Rev. Immunol., 2022, 22(2), 97-111. doi: 10.1038/s41577-021-00557-4 PMID: 34099898
Gate, D.; Saligrama, N.; Leventhal, O.; Yang, A.C.; Unger, M.S.; Middeldorp, J.; Chen, K.; Lehallier, B.; Channappa, D.; De Los Santos, M.B.; McBride, A.; Pluvinage, J.; Elahi, F.; Tam, G.K.Y.; Kim, Y.; Greicius, M.; Wagner, A.D.; Aigner, L.; Galasko, D.R.; Davis, M.M.; Wyss-Coray, T. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimers disease. Nature, 2020, 577(7790), 399-404. doi: 10.1038/s41586-019-1895-7 PMID: 31915375
Mietelska-Porowska, A.; Wojda, U. T lymphocytes and inflammatory mediators in the interplay between brain and blood in Alzheimers disease: Potential pools of new biomarkers. J. Immunol. Res., 2017, 2017, 1-17. doi: 10.1155/2017/4626540 PMID: 28293644
Rezai-Zadeh, K.; Gate, D.; Town, T. CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? J. Neuroimmune Pharmacol., 2009, 4(4), 462-475. doi: 10.1007/s11481-009-9166-2 PMID: 19669892
Dai, L.; Shen, Y. Insights into Tcell dysfunction in Alzheimers disease. Aging Cell, 2021, 20(12), e13511. doi: 10.1111/acel.13511 PMID: 34725916
Machhi, J.; Yeapuri, P.; Lu, Y.; Foster, E.; Chikhale, R.; Herskovitz, J.; Namminga, K.L.; Olson, K.E.; Abdelmoaty, M.M.; Gao, J.; Quadros, R.M.; Kiyota, T.; Jingjing, L.; Kevadiya, B.D.; Wang, X.; Liu, Y.; Poluektova, L.Y.; Gurumurthy, C.B.; Mosley, R.L.; Gendelman, H.E. CD4+ effector T cells accelerate Alzheimers disease in mice. J. Neuroinflammation, 2021, 18(1), 272. doi: 10.1186/s12974-021-02308-7 PMID: 34798897
Monsonego, A.; Zota, V.; Karni, A.; Krieger, J.I.; Bar-Or, A.; Bitan, G.; Budson, A.E.; Sperling, R.; Selkoe, D.J.; Weiner, H.L. Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease. J. Clin. Invest., 2003, 112(3), 415-422. doi: 10.1172/JCI200318104 PMID: 12897209
Kustrimovic, N.; Comi, C.; Magistrelli, L.; Rasini, E.; Legnaro, M.; Bombelli, R.; Aleksic, I.; Blandini, F.; Minafra, B.; Riboldazzi, G.; Sturchio, A.; Mauri, M.; Bono, G.; Marino, F.; Cosentino, M. Parkinsons disease patients have a complex phenotypic and functional Th1 bias: Cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients. J. Neuroinflammation, 2018, 15(1), 205. doi: 10.1186/s12974-018-1248-8 PMID: 30001736
Saunders, J.A.H.; Estes, K.A.; Kosloski, L.M.; Allen, H.E.; Dempsey, K.M.; Torres-Russotto, D.R.; Meza, J.L.; Santamaria, P.M.; Bertoni, J.M.; Murman, D.L.; Ali, H.H.; Standaert, D.G.; Mosley, R.L.; Gendelman, H.E. CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinsons disease. J. Neuroimmune Pharmacol., 2012, 7(4), 927-938. doi: 10.1007/s11481-012-9402-z PMID: 23054369
Xu, Y.; Li, Y.; Wang, C.; Han, T.; Liu, H.; Sun, L.; Hong, J.; Hashimoto, M.; Wei, J. The reciprocal interactions between microglia and T cells in Parkinsons disease: A double-edged sword. J. Neuroinflammation, 2023, 20(1), 33. doi: 10.1186/s12974-023-02723-y PMID: 36774485
Vacinova, G.; Vejrakova, D.; Rusina, R.; Holmerová, I.; Vaňková, H.; Jarolímová, E.; Včelák, J.; Bendlová, B.; Vaňková, M. Regulated upon activation, normal T cell expressed and secreted (RANTES) levels in the peripheral blood of patients with Alzheimers disease. Neural Regen. Res., 2021, 16(4), 796-800. doi: 10.4103/1673-5374.295340 PMID: 33063745
Schwartz, M.; Baruch, K. Breaking peripheral immune tolerance to CNS antigens in neurodegenerative diseases: Boosting autoimmunity to fight-off chronic neuroinflammation. J. Autoimmun., 2014, 54, 8-14. doi: 10.1016/j.jaut.2014.08.002
Chen, X.; Firulyova, M.; Manis, M.; Herz, J.; Smirnov, I.; Aladyeva, E.; Wang, C.; Bao, X.; Finn, M.B.; Hu, H.; Shchukina, I.; Kim, M.W.; Yuede, C.M.; Kipnis, J.; Artyomov, M.N.; Ulrich, J.D.; Holtzman, D.M. Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy. Nature, 2023, 615(7953), 668-677. doi: 10.1038/s41586-023-05788-0 PMID: 36890231
Subbarayan, M.S.; Hudson, C.; Moss, L.D.; Nash, K.R.; Bickford, P.C. T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an α-synuclein rat model of Parkinsons disease. J. Neuroinflammation, 2020, 17(1), 242. doi: 10.1186/s12974-020-01911-4 PMID: 32799878
Cai, H.Y.; Fu, X.X.; Jiang, H.; Han, S. Adjusting vascular permeability, leukocyte infiltration, and microglial cell activation to rescue dopaminergic neurons in rodent models of Parkinsons disease. NPJ Parkinsons Dis., 2021, 7(1), 91. doi: 10.1038/s41531-021-00233-3 PMID: 34625569
Liu, Y.; Sorce, S.; Nuvolone, M.; Domange, J.; Aguzzi, A. Lymphocyte activation gene 3 (Lag3) expression is increased in prion infections but does not modify disease progression. Sci. Rep., 2018, 8(1), 14600. doi: 10.1038/s41598-018-32712-8 PMID: 30279468
Guo, W.; Zhou, M.; Qiu, J.; Lin, Y.; Chen, X.; Huang, S.; Mo, M.; Liu, H.; Peng, G.; Zhu, X.; Xu, P. Association of LAG3 genetic variation with an increased risk of PD in Chinese female population. J. Neuroinflammation, 2019, 16(1), 270. doi: 10.1186/s12974-019-1654-6 PMID: 31847878
García-Martín, E.; Pastor, P.; Gómez-Tabales, J.; Alonso-Navarro, H.; Alvarez, I.; Buongiorno, M.; Cerezo-Arias, M.O.; Aguilar, M.; Agúndez, J.A.G.; Jiménez-Jiménez, F.J. Association between LAG3/CD4 gene variants and risk of Parkinsons disease. Eur. J. Clin. Invest., 2022, 52(11), e13847. doi: 10.1111/eci.13847 PMID: 36224715
Cui, S.; Du, J.J.; Liu, S.H.; Meng, J.; Lin, Y.Q.; Li, G.; He, Y.X.; Zhang, P.C.; Chen, S.; Wang, G. Serum soluble lymphocyte activation gene3 as a diagnostic biomarker in Parkinsons disease: A pilot multicenter study. Mov. Disord., 2019, 34(1), 138-141. doi: 10.1002/mds.27569 PMID: 30485547
Roy, A.; Choudhury, S.; Banerjee, R.; Basu, P.; Kumar, H. Soluble LAG-3 and Toll-interacting protein: Novel upstream neuro-inflammatory markers in Parkinsons disease. Parkinsonism Relat. Disord., 2021, 91, 121-123. doi: 10.1016/j.parkreldis.2021.09.019 PMID: 34601340
Saresella, M.; Calabrese, E.; Marventano, I.; Piancone, F.; Gatti, A.; Calvo, M.G.; Nemni, R.; Clerici, M. PD1 negative and PD1 positive CD4+ T regulatory cells in mild cognitive impairment and Alzheimers disease. J. Alzheimers Dis., 2010, 21(3), 927-938. doi: 10.3233/JAD-2010-091696 PMID: 20634592
Olson, K.E.; Mosley, R.L.; Gendelman, H.E. The potential for treg-enhancing therapies in nervous system pathologies. Clin. Exp. Immunol., 2022, uxac084. PMID: 36041453
Beers, D.R.; Zhao, W.; Wang, J.; Zhang, X.; Wen, S.; Neal, D.; Thonhoff, J.R.; Alsuliman, A.S.; Shpall, E.J.; Rezvani, K.; Appel, S.H. ALS patients regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight, 2017, 2(5), e89530. doi: 10.1172/jci.insight.89530 PMID: 28289705
Schröder, J.B.; Pawlowski, M.; Meyer zu Hörste, G.; Gross, C.C.; Wiendl, H.; Meuth, S.G.; Ruck, T.; Warnecke, T. Immune cell activation in the cerebrospinal fluid of patients with Parkinsons disease. Front. Neurol., 2018, 9, 1081. doi: 10.3389/fneur.2018.01081 PMID: 30619041
Stym-Popper, G.; Matta, K.; Chaigneau, T.; Rupra, R.; Demetriou, A.; Fouquet, S.; Dansokho, C.; Toly-Ndour, C.; Dorothée, G. Regulatory T cells decrease C3-positive reactive astrocytes in Alzheimer-like pathology. J. Neuroinflammation, 2023, 20(1), 64. doi: 10.1186/s12974-023-02702-3 PMID: 36890536
Ciccocioppo, F.; Lanuti, P.; Pierdomenico, L.; Simeone, P.; Bologna, G.; Ercolino, E.; Buttari, F.; Fantozzi, R.; Thomas, A.; Onofrj, M.; Centonze, D.; Miscia, S.; Marchisio, M. The characterization of regulatory t-cell profiles in Alzheimers disease and multiple sclerosis. Sci. Rep., 2019, 9(1), 8788. doi: 10.1038/s41598-019-45433-3
Baruch, K.; Rosenzweig, N.; Kertser, A.; Deczkowska, A.; Sharif, A.M.; Spinrad, A.; Tsitsou-Kampeli, A.; Sarel, A.; Cahalon, L.; Schwartz, M. Breaking immune tolerance by targeting Foxp3+ regulatory T cells mitigates Alzheimers disease pathology. Nat. Commun., 2015, 6(1), 7967. doi: 10.1038/ncomms8967 PMID: 26284939
Novakova Martinkova, J.; Ferretti, M.T.; Ferrari, A.; Lerch, O.; Matuskova, V.; Secnik, J.; Hort, J. Longitudinal progression of choroid plexus enlargement is associated with female sex, cognitive decline and ApoE E4 homozygote status. Front. Psychiatry, 2023, 14, 1039239. doi: 10.3389/fpsyt.2023.1039239 PMID: 36970283
Yang, H.; Park, S.Y.; Baek, H.; Lee, C.; Chung, G.; Liu, X.; Lee, J.H.; Kim, B.; Kwon, M.; Choi, H.; Kim, H.J.; Kim, J.Y.; Kim, Y.; Lee, Y.S.; Lee, G.; Kim, S.K.; Kim, J.S.; Chang, Y.T.; Jung, W.S.; Kim, K.H.; Bae, H. Adoptive therapy with amyloid-β specific regulatory T cells alleviates Alzheimers disease. Theranostics, 2022, 12(18), 7668-7680. doi: 10.7150/thno.75965 PMID: 36451854
Moore, J.R.; Hubler, S.L.; Nelson, C.D.; Nashold, F.E.; Spanier, J.A.; Hayes, C.E. 1,25-Dihydroxyvitamin D3 increases the methionine cycle, CD4+ T cell DNA methylation and Helios+Foxp3+ T regulatory cells to reverse autoimmune neurodegenerative disease. J. Neuroimmunol., 2018, 324, 100-114. doi: 10.1016/j.jneuroim.2018.09.008 PMID: 30267995
Janjusevic, M.; Gagno, G.; Fluca, A.L.; Padoan, L.; Beltrami, A.P.; Sinagra, G.; Moretti, R.; Aleksova, A. The peculiar role of vitamin D in the pathophysiology of cardiovascular and neurodegenerative diseases. Life Sci., 2022, 289, 120193. doi: 10.1016/j.lfs.2021.120193 PMID: 34864062
Shi, Y.; Wei, B.; Li, L.; Wang, B.; Sun, M. Th17 cells and inflammation in neurological disorders: Possible mechanisms of action. Front. Immunol., 2022, 13, 932152. doi: 10.3389/fimmu.2022.932152 PMID: 35935951
Sommer, A.; Marxreiter, F.; Krach, F.; Fadler, T.; Grosch, J.; Maroni, M.; Graef, D.; Eberhardt, E.; Riemenschneider, M.J.; Yeo, G.W.; Kohl, Z.; Xiang, W.; Gage, F.H.; Winkler, J.; Prots, I.; Winner, B. Th17 lymphocytes induce neuronal cell death in a human iPSC-based model of Parkinsons disease. Cell Stem Cell, 2019, 24(6), 1006. doi: 10.1016/j.stem.2019.04.019 PMID: 31173705
Li, J. Zhao, J.; Chen, L.; Gao, H.; Zhang, J.; Wang, D.; Zou, Y.; Qin, Q.; Qu, Y.; Li, J.; Xiong, Y.; Min, Z.; Yan, M.; Mao, Z.; Xue, Z. α-Synuclein induces Th17 differentiation and impairs the function and stability of Tregs by promoting RORC transcription in Parkinsons disease. Brain Behav. Immun., 2023, 108, 32-44. doi: 10.1016/j.bbi.2022.10.023 PMID: 36343753
Mohammadi, S., V.; Ravari, A.; Mirzaei, T.; Zare-Bidaki, M.; Asadikaram, G.; Arababadi, M.K. IL-17A and IL-23: Plausible risk factors to induce age-associated inflammation in Alzheimers disease. Immunol. Invest., 2018, 47(8), 812-822. doi: 10.1080/08820139.2018.1504300 PMID: 30081688
Biragyn, A.; Aliseychik, M.; Rogaev, E. Potential importance of B cells in aging and aging-associated neurodegenerative diseases. Semin. Immunopathol., 2017, 39(3), 283-294. doi: 10.1007/s00281-016-0615-8 PMID: 28083646
Sabatino, J.J., Jr; Pröbstel, A.K.; Zamvil, S.S. B cells in autoimmune and neurodegenerative central nervous system diseases. Nat. Rev. Neurosci., 2019, 20(12), 728-745. doi: 10.1038/s41583-019-0233-2 PMID: 31712781
Orr, C.F.; Rowe, D.B.; Mizuno, Y.; Mori, H.; Halliday, G.M. A possible role for humoral immunity in the pathogenesis of Parkinsons disease. Brain, 2005, 128(11), 2665-2674. doi: 10.1093/brain/awh625 PMID: 16219675
Du, Y.; Dodel, R.; Hampel, H.; Buerger, K.; Lin, S.; Eastwood, B.; Bales, K.; Gao, F.; Moeller, H.J.; Oertel, W.; Farlow, M.; Paul, S. Reduced levels of amyloid -peptide antibody in Alzheimer disease. Neurology, 2001, 57(5), 801-805. doi: 10.1212/WNL.57.5.801 PMID: 11552007
Hyman, B.T.; Smith, C.; Buldyrev, I.; Whelan, C.; Brown, H.; Tang, M.X.; Mayeux, R. Autoantibodies to amyloid-? and Alzheimers disease. Ann. Neurol., 2001, 49(6), 808-810. doi: 10.1002/ana.1061 PMID: 11409436
Weksler, M.E.; Relkin, N.; Turkenich, R.; LaRusse, S.; Zhou, L.; Szabo, P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol., 2002, 37(7), 943-948. doi: 10.1016/S0531-5565(02)00029-3 PMID: 12086704
DeMarshall, C.A.; Viviano, J.; Emrani, S.; Thayasivam, U.; Godsey, G.A.; Sarkar, A.; Belinka, B.; Libon, D.J.; Nagele, R.G. Early detection of alzheimers disease-related pathology using a multi-disease diagnostic platform employing autoantibodies as blood-based biomarkers. J. Alzheimers Dis., 2023, 92(3), 1077-1091. doi: 10.3233/JAD-221091 PMID: 36847005
Carvey, P.M.; McRae, A.; Lint, T.F.; Ptak, L.R.; Lo, E.S.; Goetz, C.G.; Klawans, H.L. The potential use of a dopamine neuron antibody and a striatal-derived neurotrophic factor as diagnostic markers in Parkinsons disease., Neurology, 1991, 41 (5, Supplement 2)(2), 53-58. doi: 10.1212/WNL.41.5_Suppl_2.53 PMID: 2041594
Chen, S.; Le, W.D.; Xie, W.J.; Alexianu, M.E.; Engelhardt, J.I.; Siklós, L.; Appel, S.H. Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. Arch. Neurol., 1998, 55(8), 1075-1080. doi: 10.1001/archneur.55.8.1075 PMID: 9708957
Le, W.D.; Rowe, D.B.; Jankovic, J.; Xie, W.; Appel, S.H. Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. Arch. Neurol., 1999, 56(2), 194-200. doi: 10.1001/archneur.56.2.194 PMID: 10025424
Papachroni, K.K.; Ninkina, N.; Papapanagiotou, A.; Hadjigeorgiou, G.M.; Xiromerisiou, G.; Papadimitriou, A.; Kalofoutis, A.; Buchman, V.L. Autoantibodies to alpha-synuclein in inherited Parkinsons disease. J. Neurochem., 2007, 101(3), 749-756. doi: 10.1111/j.1471-4159.2006.04365.x PMID: 17448146
Shalash, A.; Salama, M.; Makar, M.; Roushdy, T.; Elrassas, H.H.; Mohamed, W.; El-Balkimy, M.; Abou, D.M. Elevated serum α-synuclein autoantibodies in patients with Parkinsons disease relative to Alzheimers disease and controls. Front. Neurol., 2017, 8, 720. doi: 10.3389/fneur.2017.00720 PMID: 29312137
Besong-Agbo, D.; Wolf, E.; Jessen, F.; Oechsner, M.; Hametner, E.; Poewe, W.; Reindl, M.; Oertel, W.H.; Noelker, C.; Bacher, M.; Dodel, R. Naturally occurring -synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology, 2013, 80(2), 169-175. doi: 10.1212/WNL.0b013e31827b90d1 PMID: 23255825
Horvath, I.; Iashchishyn, I.A.; Forsgren, L.; Morozova-Roche, L.A. Immunochemical detection of α-synuclein autoantibodies in Parkinsons disease: Correlation between plasma and cerebrospinal fluid levels. ACS Chem. Neurosci., 2017, 8(6), 1170-1176. doi: 10.1021/acschemneuro.7b00063 PMID: 28263550
Akhtar, R.S.; Licata, J.P.; Luk, K.C.; Shaw, L.M.; Trojanowski, J.Q.; Lee, V.M.Y. Measurements of auto-antibodies to α-synuclein in the serum and cerebral spinal fluids of patients with Parkinsons disease. J. Neurochem., 2018, 145(6), 489-503. doi: 10.1111/jnc.14330 PMID: 29500813
Double, K.L.; Rowe, D.B.; Carew-Jones, F.M.; Hayes, M.; Chan, D.K.Y.; Blackie, J.; Corbett, A.; Joffe, R.; Fung, V.S.; Morris, J.; Riederer, P.; Gerlach, M.; Halliday, G.M. Anti-melanin antibodies are increased in sera in Parkinsons disease. Exp. Neurol., 2009, 217(2), 297-301. doi: 10.1016/j.expneurol.2009.03.002 PMID: 19289120
Zappia, M.; Crescibene, L.; Bosco, D.; Arabia, G.; Nicoletti, G.; Bagalà, A.; Bastone, L.; Napoli, I.D.; Caracciolo, M.; Bonavita, S.; Di Costanzo, A.; Gambardella, A.; Quattrone, A. Anti-GM1 ganglioside antibodies in Parkinsons disease. Acta Neurol. Scand., 2002, 106(1), 54-57. doi: 10.1034/j.1600-0404.2002.01240.x PMID: 12067330
De Virgilio, A.; Greco, A.; Fabbrini, G.; Inghilleri, M.; Rizzo, M.I.; Gallo, A.; Conte, M.; Rosato, C.; Ciniglio Appiani, M.; de Vincentiis, M. Parkinsons disease: Autoimmunity and neuroinflammation. Autoimmun. Rev., 2016, 15(10), 1005-1011. doi: 10.1016/j.autrev.2016.07.022 PMID: 27497913
Benkler, M.; Agmon-Levin, N.; Hassin-Baer, S.; Cohen, O.S.; Ortega-Hernandez, O.D.; Levy, A.; Moscavitch, S.D.; Szyper-Kravitz, M.; Damianovich, M.; Blank, M.; Chapman, J.; Shoenfeld, Y. Immunology, autoimmunity, and autoantibodies in Parkinsons disease. Clin. Rev. Allergy Immunol., 2012, 42(2), 164-171. doi: 10.1007/s12016-010-8242-y PMID: 21234712
Papuć, E.; Rejdak, K. Anti-MAG autoantibodies are increased in Parkinsons disease but not in atypical parkinsonism. J. Neural Transm., 2017, 124(2), 209-216. doi: 10.1007/s00702-016-1632-4 PMID: 27766424
Honorat, J.A.; McKeon, A. Autoimmune movement disorders: A clinical and laboratory approach. Curr. Neurol. Neurosci. Rep., 2017, 17(1), 4. doi: 10.1007/s11910-017-0709-2 PMID: 28120141
Caggiu, E.; Paulus, K.; Arru, G.; Piredda, R.; Sechi, G.P.; Sechi, L.A. Humoral cross reactivity between α-synuclein and herpes simplex-1 epitope in Parkinsons disease, a triggering role in the disease? J. Neuroimmunol., 2016, 291, 110-114. doi: 10.1016/j.jneuroim.2016.01.007 PMID: 26857504
Cebrián, C.; Zucca, F.A.; Mauri, P.; Steinbeck, J.A.; Studer, L.; Scherzer, C.R.; Kanter, E.; Budhu, S.; Mandelbaum, J.; Vonsattel, J.P.; Zecca, L.; Loike, J.D.; Sulzer, D. MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat. Commun., 2014, 5(1), 3633. doi: 10.1038/ncomms4633 PMID: 24736453
Jiang, T.; Li, G.; Xu, J.; Gao, S.; Chen, X. The challenge of the pathogenesis of parkinsons disease: Is autoimmunity the culprit? Front. Immunol., 2018, 9, 2047. doi: 10.3389/fimmu.2018.02047 PMID: 30319601
Oberländer, U.; Pletinckx, K.; Döhler, A.; Müller, N.; Lutz, M.B.; Arzberger, T.; Riederer, P.; Gerlach, M.; Koutsilieri, E.; Scheller, C. Neuromelanin is an immune stimulator for dendritic cells in vitro. BMC Neurosci., 2011, 12(1), 116. doi: 10.1186/1471-2202-12-116 PMID: 22085464
Koutsilieri, E.; Lutz, M.B.; Scheller, C. Autoimmunity, dendritic cells and relevance for Parkinsons disease. J. Neural Transm., 2013, 120(1), 75-81. doi: 10.1007/s00702-012-0842-7 PMID: 22699458
Depboylu, C.; Schäfer, M.K.H.; Arias-Carrión, O.; Oertel, W.H.; Weihe, E.; Höglinger, G.U. Possible involvement of complement factor C1q in the clearance of extracellular neuromelanin from the substantia nigra in Parkinson disease. J. Neuropathol. Exp. Neurol., 2011, 70(2), 125-132. doi: 10.1097/NEN.0b013e31820805b9 PMID: 21343881
Alberici, A.; Cristillo, V.; Gazzina, S.; Benussi, A.; Padovani, A.; Borroni, B. Autoimmunity and frontotemporal dementia. Curr. Alzheimer Res., 2018, 15(7), 602-609. doi: 10.2174/1567205015666180119104825 PMID: 29357796
Palese, F.; Bonomi, E.; Nuzzo, T.; Benussi, A.; Mellone, M.; Zianni, E.; Cisani, F.; Casamassa, A.; Alberici, A.; Scheggia, D.; Padovani, A.; Marcello, E.; Di Luca, M.; Pittaluga, A.; Usiello, A.; Borroni, B.; Gardoni, F. Anti-GluA3 antibodies in frontotemporal dementia: Effects on glutamatergic neurotransmission and synaptic failure. Neurobiol. Aging, 2020, 86, 143-155. doi: 10.1016/j.neurobiolaging.2019.10.015 PMID: 31784278
Arshad, F.; Varghese, F.; Paplikar, A.; Gangadhar, Y.; Ramakrishnan, S.; Chaudhuri, J.R.; Mahadevan, A.; Alladi, S. Role of autoantibodies in neurodegenerative dementia: An emerging association. Dement. Geriatr. Cogn. Disord., 2021, 50(2), 153-160. doi: 10.1159/000517238 PMID: 34237731
Maftei, M.; Thurm, F.; Schnack, C.; Tumani, H.; Otto, M.; Elbert, T.; Kolassa, I.T.; Przybylski, M.; Manea, M.; von Arnim, C.A.F. Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimers disease patients. PLoS One, 2013, 8(7), e68996. doi: 10.1371/journal.pone.0068996 PMID: 23874844
Bartos, A.; Fialová, L.; varcová, J. Lower serum antibodies against tau protein and heavy neurofilament in alzheimers disease. J. Alzheimers Dis., 2018, 64(3), 751-760. doi: 10.3233/JAD-180039 PMID: 29966192
Koval, L.; Lykhmus, O.; Kalashnyk, O.; Bachinskaya, N.; Kravtsova, G.; Soldatkina, M.; Zouridakis, M.; Stergiou, C.; Tzartos, S.; Tsetlin, V.; Komisarenko, S.; Skok, M. The presence and origin of autoantibodies against α4 and α7 nicotinic acetylcholine receptors in the human blood: Possible relevance to Alzheimers pathology. J. Alzheimers Dis., 2011, 25(4), 747-761. doi: 10.3233/JAD-2011-101845 PMID: 21593571
Davydova, T.V.; Mikovskaya, O.I.; Fomina, V.G.; Voskresenskaya, N.I.; Doronina, O.A. Induction of immune complexes and autoantibodies to serotonin and dopamine in patients with Alzheimers disease. Bull. Exp. Biol. Med., 2002, 134(1), 23-25. doi: 10.1023/A:1020692218416 PMID: 12459860
Davydova, T.V.; Voskresenskaya, N.I.; Gorbatov, V.Y.; Fomina, V.G.; Doronina, O.A.; Maksunova, I.V. Production of autoantibodies to glutamate during Alzheimers dementia. Bull. Exp. Biol. Med., 2009, 147(4), 405-407. doi: 10.1007/s10517-009-0530-2 PMID: 19704934
Busse, S.; Brix, B.; Kunschmann, R.; Bogerts, B.; Stoecker, W.; Busse, M. N-methyl-d-aspartate glutamate receptor (NMDA-R) antibodies in mild cognitive impairment and dementias. Neurosci. Res., 2014, 85, 58-64. doi: 10.1016/j.neures.2014.06.002 PMID: 24973618
Gruden, M.A.; Davidova, T.B.; Maliauskas, M.; Sewell, R.D.E.; Voskresenskaya, N.I.; Wilhelm, K.; Elistratova, E.I.; Sherstnev, V.V.; Morozova-Roche, L.A. Differential neuroimmune markers to the onset of Alzheimers disease neurodegeneration and dementia: Autoantibodies to Aβ(2535) oligomers, S100b and neurotransmitters. J. Neuroimmunol., 2007, 186(1-2), 181-192. doi: 10.1016/j.jneuroim.2007.03.023 PMID: 17477976
Mecocci, P.; Parnetti, L.; Donato, R.; Santucci, C.; Santucci, A.; Cadini, D.; Foà, E.; Cecchetti, R.; Senin, U. Serum autoantibodies against glial fibrillary acidic protein in brain aging and senile dementias. Brain Behav. Immun., 1992, 6(3), 286-292. doi: 10.1016/0889-1591(92)90049-T PMID: 1392102
McRae, A.; Dahlström, A.; Polinsky, R.; Ling, E.A. Cerebrospinal fluid microglial antibodies: Potential diagnostic markers for immune mechanisms in Alzheimers disease. Behav. Brain Res., 1993, 57(2), 225-234. doi: 10.1016/0166-4328(93)90139-H PMID: 8117427
Kingsley, B.S.; Gaskin, F.; Fu, S.M. Human antibodies to neurofibrillary tangles and astrocytes in Alzheimers disease. J. Neuroimmunol., 1988, 19(1-2), 89-99. doi: 10.1016/0165-5728(88)90038-0 PMID: 3260906
Kankaanpää, J.; Turunen, S.P.; Moilanen, V.; Hörkkö, S.; Remes, A.M. Cerebrospinal fluid antibodies to oxidized LDL are increased in Alzheimers disease. Neurobiol. Dis., 2009, 33(3), 467-472. doi: 10.1016/j.nbd.2008.12.001 PMID: 19130885
Vojdani, A.; Vojdani, E. Amyloid-Beta 1-42 cross-reactive antibody prevalent in human sera may contribute to intraneuronal deposition of A-Beta-P-42. Int. J. Alzheimers Dis., 2018, 2018, 1-12. doi: 10.1155/2018/1672568 PMID: 30034864
Mruthinti, S.; Schade, R.; Harrell, D.; Gulati, N.; Swamy-Mruthinti, S.; Lee, G.; Buccafusco, J. Autoimmunity in Alzheimers disease as evidenced by plasma immunoreactivity against RAGE and Abeta42: Complication of diabetes. Curr. Alzheimer Res., 2006, 3(3), 229-235. doi: 10.2174/156720506777632899 PMID: 16842100
Giil, L.M.; Kristoffersen, E.K.; Vedeler, C.A.; Aarsland, D.; Nordrehaug, J.E.; Winblad, B.; Cedazo-Minguez, A.; Lund, A.; Reksten, T.R. Autoantibodies toward the angiotensin 2 Type 1 receptor: A novel autoantibody in alzheimers disease. J. Alzheimers Dis., 2015, 47(2), 523-529. doi: 10.3233/JAD-150053 PMID: 26401573
Colasanti, T.; Barbati, C.; Rosano, G.; Malorni, W.; Ortona, E. Autoantibodies in patients with Alzheimers disease: Pathogenetic role and potential use as biomarkers of disease progression. Autoimmun. Rev., 2010, 9(12), 807-811. doi: 10.1016/j.autrev.2010.07.008 PMID: 20656067
Ariga, T.; Jarvis, W.D.; Yu, R.K. Role of sphingolipid-mediated cell death in neurodegenerative diseases. J. Lipid Res., 1998, 39(1), 1-16. doi: 10.1016/S0022-2275(20)34198-5 PMID: 9469581
Jianming, W.; Ling, L. Autoantibodies in Alzheimers disease: Potential biomarkers, pathogenic roles, and therapeutic implications. J. Biomed. Res., 2016, 30(5), 361-372. doi: 10.7555/JBR.30.20150131 PMID: 27476881
Vacirca, D.; Delunardo, F.; Matarrese, P.; Colasanti, T.; Margutti, P.; Siracusano, A.; Pontecorvo, S.; Capozzi, A.; Sorice, M.; Francia, A.; Malorni, W.; Ortona, E. Autoantibodies to the adenosine triphosphate synthase play a pathogenetic role in Alzheimers disease. Neurobiol. Aging, 2012, 33(4), 753-766. doi: 10.1016/j.neurobiolaging.2010.05.013 PMID: 20594618
Berry, A.; Vacirca, D.; Capoccia, S.; Bellisario, V.; Malorni, W.; Ortona, E.; Cirulli, F. Anti-ATP synthase autoantibodies induce neuronal death by apoptosis and impair cognitive performance in C57BL/6J mice. J. Alzheimers Dis., 2012, 33(2), 317-321. doi: 10.3233/JAD-2012-121312 PMID: 22954670
Dinkins, M.B.; Dasgupta, S.; Wang, G.; Zhu, G.; He, Q.; Kong, J.N.; Bieberich, E. The 5XFAD mouse model of Alzheimers disease exhibits an age-dependent increase in anti-ceramide IgG and exogenous administration of ceramide further increases anti-ceramide titers and amyloid plaque burden. J. Alzheimers Dis., 2015, 46(1), 55-61. doi: 10.3233/JAD-150088 PMID: 25720409
Li, X.; Sundquist, J.; Sundquist, K. Subsequent risks of Parkinson disease in patients with autoimmune and related disorders: A nationwide epidemiological study from Sweden. Neurodegener. Dis., 2012, 10(1-4), 277-284. doi: 10.1159/000333222 PMID: 22205172
Li, X.; Sundquist, J.; Zöller, B.; Sundquist, K. Dementia and Alzheimers disease risks in patients with autoimmune disorders. Geriatr. Gerontol. Int., 2018, 18(9), 1350-1355. doi: 10.1111/ggi.13488 PMID: 30044040
Cho, Y.Y.; Kim, B.; Shin, D.W.; Youn, J.; Mok, J.O.; Kim, C.H.; Kim, S.W.; Chung, J.H.; Han, K.; Kim, T.H. Graves disease and the risk of Parkinsons disease: A Korean population-based study. Brain Commun., 2022, 4(1), fcac014. doi: 10.1093/braincomms/fcac014 PMID: 35187486
Bonuccelli, U.; DAvino, C.; Caraccio, N.; Del Guerra, P.; Casolaro, A.; Pavese, N.; Del Dotto, P.; Monzani, F. Thyroid function and autoimmunity in Parkinsons disease: A study of 101 patients. Parkinsonism Relat. Disord., 1999, 5(1-2), 49-53. doi: 10.1016/S1353-8020(99)00010-3 PMID: 18591119
Charoenngam, N.; Rittiphairoj, T.; Ponvilawan, B.; Prasongdee, K. Thyroid dysfunction and risk of Parkinsons disease: A systematic review and meta-analysis. Front. Endocrinol., 2022, 13, 863281. doi: 10.3389/fendo.2022.863281 PMID: 35600588
Yeung, C.H.C.; Au Yeung, S.L.; Schooling, C.M. Association of autoimmune diseases with Alzheimers disease: A mendelian randomization study. J. Psychiatr. Res., 2022, 155, 550-558. doi: 10.1016/j.jpsychires.2022.09.052 PMID: 36198219
Ungprasert, P.; Wijarnpreecha, K.; Thongprayoon, C. Rheumatoid arthritis and the risk of dementia: A systematic review and meta-analysis. Neurol. India, 2016, 64(1), 56-61. doi: 10.4103/0028-3886.173623 PMID: 26754993
McDowell, B.; Marr, C.; Holmes, C.; Edwards, C.J.; Cardwell, C.; McHenry, M.; Meenagh, G.; McGuinness, B. Prevalence of cognitive impairment in patients with rheumatoid arthritis: A cross sectional study. BMC Psychiatry, 2022, 22(1), 777. doi: 10.1186/s12888-022-04417-w PMID: 36494656
Tansey, M.G.; Wallings, R.L.; Houser, M.C.; Herrick, M.K.; Keating, C.E.; Joers, V. Inflammation and immune dysfunction in Parkinson disease. Nat. Rev. Immunol., 2022, 22(11), 657-673. doi: 10.1038/s41577-022-00684-6 PMID: 35246670
Li, D.; Hong, X.; Chen, T. Association between rheumatoid arthritis and risk of Parkinsons disease: A meta-analysis and systematic review. Front. Neurol., 2022, 13, 885179. doi: 10.3389/fneur.2022.885179 PMID: 35645965
Li, M.; Wan, J.; Xu, Z.; Tang, B. The association between Parkinsons disease and autoimmune diseases: A systematic review and meta-analysis. Front. Immunol., 2023, 14, 1103053. doi: 10.3389/fimmu.2023.1103053 PMID: 36761731
Policicchio, S.; Ahmad, A.N.; Powell, J.F.; Proitsi, P. Rheumatoid arthritis and risk for Alzheimers disease: A systematic review and meta-analysis and a Mendelian Randomization study. Sci. Rep., 2017, 7(1), 12861. doi: 10.1038/s41598-017-13168-8 PMID: 28993680
Cooper, J.; Pastorello, Y.; Slevin, M. A meta-analysis investigating the relationship between inflammation in autoimmune disease, elevated CRP, and the risk of dementia. Front. Immunol., 2023, 14, 1087571. doi: 10.3389/fimmu.2023.1087571 PMID: 36776896
Karabay, E.A.; Çerman, A.A.; Altunay, İ.K. Evaluation of comorbidities in patients with autoimmune bullous diseases: A retrospective study. Sisli Etfal Hastan Tip Bul., 2018, 52(4), 302-306. PMID: 32774095
Yeh, F.C.; Chen, H.C.; Chou, Y.C.; Lin, C.L.; Kao, C.H.; Lo, H.Y.; Liu, F.C.; Yang, T.Y. Positive association of Parkinsons disease with ankylosing spondylitis: A nationwide population-based study. J. Transl. Med., 2020, 18(1), 455. doi: 10.1186/s12967-020-02629-w PMID: 33256841
Rønnow Sand, J.; Troelsen, F.S.; Horváth-Puhó, E.; Henderson, V.W.; Sørensen, H.T.; Erichsen, R. Risk of dementia in patients with inflammatory bowel disease: A Danish population-based study. Aliment. Pharmacol. Ther., 2022, 56(5), 831-843. doi: 10.1111/apt.17119 PMID: 35781292
Zhang, B.; Wang, H.E.; Bai, Y.M.; Tsai, S.J.; Su, T.P.; Chen, T.J.; Wang, Y.P.; Chen, M.H. Inflammatory bowel disease is associated with higher dementia risk: A nationwide longitudinal study. Gut, 2021, 70(1), 85-91. doi: 10.1136/gutjnl-2020-320789 PMID: 32576641
Szandruk-Bender, M.; Wiatrak, B.; Szeląg, A. The risk of developing Alzheimers disease and Parkinsons disease in patients with inflammatory bowel disease: A meta-analysis. J. Clin. Med., 2022, 11(13), 3704. doi: 10.3390/jcm11133704 PMID: 35806985
Aggarwal, M.; Alkhayyat, M.; Abou Saleh, M.; Sarmini, M.T.; Singh, A.; Garg, R.; Garg, P.; Mansoor, E.; Padival, R.; Cohen, B.L. Alzheimer disease occurs more frequently in patients with inflammatory bowel disease. J. Clin. Gastroenterol., 2023, 57(5), 501-507. doi: 10.1097/MCG.0000000000001714 PMID: 35470286
Cui, G.; Li, S.; Ye, H.; Yang, Y.; Huang, Q.; Chu, Y.; Shi, Z.; Zhang, X. Are neurodegenerative diseases associated with an increased risk of inflammatory bowel disease? A two-sample Mendelian randomization study. Front. Immunol., 2022, 13, 956005. doi: 10.3389/fimmu.2022.956005 PMID: 36159838
Li, H.; Wen, Z. Effects of ulcerative colitis and Crohns disease on neurodegenerative diseases: A Mendelian randomization study. Front. Genet., 2022, 13, 846005. doi: 10.3389/fgene.2022.846005 PMID: 36046231
Freuer, D.; Meisinger, C. Association between inflammatory bowel disease and Parkinsons disease: A Mendelian randomization study. NPJ Parkinsons Dis., 2022, 8(1), 55. doi: 10.1038/s41531-022-00318-7 PMID: 35534507
Huang, J.; Su, B.; Karhunen, V.; Gill, D.; Zuber, V.; Ahola-Olli, A.; Palaniswamy, S.; Auvinen, J.; Herzig, K.H.; Keinänen-Kiukaanniemi, S.; Salmi, M.; Jalkanen, S.; Lehtimäki, T.; Salomaa, V.; Raitakari, O.T.; Matthews, P.M.; Elliott, P.; Tsilidis, K.K.; Jarvelin, M.; Tzoulaki, I.; Dehghan, A. Inflammatory diseases, inflammatory biomarkers, and Alzheimer disease. Neurology, 2023, 100(6), e568-e581. doi: 10.1212/WNL.0000000000201489 PMID: 36384659
Liu, F.C.; Huang, W.Y.; Lin, T.Y.; Shen, C.H.; Chou, Y.C.; Lin, C.L.; Lin, K.T.; Kao, C.H. Inverse association of Parkinson disease with systemic lupus erythematosus. Medicine, 2015, 94(46), e2097. doi: 10.1097/MD.0000000000002097 PMID: 26579824
Wang, Y.C.; Lin, M.S.; Huang, A.P.H.; Wu, C.C.; Kung, W.M. Association between systemic rheumatic diseases and dementia risk: A meta-analysis. Front. Immunol., 2022, 13, 1054246. doi: 10.3389/fimmu.2022.1054246 PMID: 36439141
Jin, T.; Huang, W.; Cao, F.; Yu, X.; Guo, S.; Ying, Z.; Xu, C. Causal association between systemic lupus erythematosus and the risk of dementia: A Mendelian randomization study. Front. Immunol., 2022, 13, 1063110. doi: 10.3389/fimmu.2022.1063110 PMID: 36569847
Chen, H.; Zhang, S.M.; Hernán, M.A.; Schwarzschild, M.A.; Willett, W.C.; Colditz, G.A.; Speizer, F.E.; Ascherio, A. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol., 2003, 60(8), 1059-1064. doi: 10.1001/archneur.60.8.1059 PMID: 12925360
Chen, H.; Jacobs, E.; Schwarzschild, M.A.; McCullough, M.L.; Calle, E.E.; Thun, M.J.; Ascherio, A. Nonsteroidal antiinflammatory drug use and the risk for Parkinsons disease. Ann. Neurol., 2005, 58(6), 963-967. doi: 10.1002/ana.20682 PMID: 16240369
Gagne, J.J.; Power, M.C. Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis. Neurology, 2010, 74(12), 995-1002. doi: 10.1212/WNL.0b013e3181d5a4a3 PMID: 20308684
Gao, X.; Chen, H.; Schwarzschild, M.A.; Ascherio, A. Use of ibuprofen and risk of Parkinson disease. Neurology, 2011, 76(10), 863-869. doi: 10.1212/WNL.0b013e31820f2d79 PMID: 21368281
Powers, K.M.; Kay, D.M.; Factor, S.A.; Zabetian, C.P.; Higgins, D.S.; Samii, A.; Nutt, J.G.; Griffith, A.; Leis, B.; Roberts, J.W.; Martinez, E.D.; Montimurro, J.S.; Checkoway, H.; Payami, H. Combined effects of smoking, coffee, and NSAIDs on Parkinsons disease risk. Mov. Disord., 2008, 23(1), 88-95. doi: 10.1002/mds.21782 PMID: 17987647
San Luciano, M.; Tanner, C.M.; Meng, C.; Marras, C.; Goldman, S.M.; Lang, A.E.; Tolosa, E.; Schüle, B.; Langston, J.W.; Brice, A.; Corvol, J.C.; Goldwurm, S.; Klein, C.; Brockman, S.; Berg, D.; Brockmann, K.; Ferreira, J.J.; Tazir, M.; Mellick, G.D.; Sue, C.M.; Hasegawa, K.; Tan, E.K.; Bressman, S.; Saunders-Pullman, R.; Saunders-Pullman, R.; Raymond, D.; Deik, A.; Barrett, M.J.; Cabassa, J.; Groves, M.; Hunt, A.L.; Lubarr, N.; Miravite, J.; Palmese, C.; Sachdev, R.; Sarva, H.; Severt, L.; Shanker, V.; Swan, M.C.; Soto-Valencia, J.; Johannes, B.; Ortega, R.; Ozelius, L.; Bressman, S.; Alcalay, R.N.; Tang, M-X.; Santana, H.M.; Roos, E.; Orbe-Reilly, M.; Fahn, S.; Cote, L.; Waters, C.; Mazzoni, P.; Ford, B.; Louis, E.; Levy, O.; Rosado, L.; Ruiz, D.; Dorovski, T.; Clark, L.; Marder, K.S.; Corvol, J-C.; Cormier, F.; Bonnet, A-M.; Welter, M-L.; Mesnage, V.; Vidailhet, M.; Roze, E.; Lacomblez, L.; Grabli, D.; Mart i Masso, J.F.; Martinez, J.R.; Mondragon, R.E.; Alustiza, A.E.; Pagola, A.G.; Pont-Sunyer, C.; Rolan, D.V.; Fernandez-Santiago, R.; Quintana, M.; Fernandez, M.; Maragall, L.; Hentati, F.; Farrer, M.; Duda, J.; Read, M.; Middleton, L.; Gibson, R.; Trinh, J.; Sassi, S.B.; Zouari, M.; Rimamouri,; Farhat, E.; Nabli, F.; Aasly, J.; Warø, B.J.; Andersen, S.; Bertoni, J.; Carter, J.; Elmer, L.; Jimenez, N.G.; Martin, W.; Pahwa, R.; Lyons, K.; Reich, S.; Rodnitzky, R.; Ramos, C.S.; Wojcieszek, J.; Mirelman, A.; Gurevich, T.; Shira, A.B.; Weisz, M.G.; Yasinovsky, K.; Zalis, M.; Thaler, A.; Orr-Urtreger, A.; Giladi, N.; Mountain, J.; Mestre, T.; Visanji, N.; Ghate, T.; Singerman, J.; Al Dakheel, A.; Connolly, B.S.; Gasser, T.; Brockmann, K.; Conley, E.D.; Mullins, M.E.; Northover, C.; Facheris, M.; Fiske, B.; Urkowiz, A. Nonsteroidal anti-inflammatory use and LRRK2 Parkinsons disease penetrance. Mov. Disord., 2020, 35(10), 1755-1764. doi: 10.1002/mds.28189 PMID: 32662532
Ren, L.; Yi, J.; Yang, J.; Li, P.; Cheng, X.; Mao, P. Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease. Medicine, 2018, 97(37), e12172. doi: 10.1097/MD.0000000000012172 PMID: 30212946
Brakedal, B.; Tzoulis, C.; Tysnes, O.B.; Haugarvoll, K. NSAID use is not associated with Parkinsons disease incidence: A Norwegian Prescription Database study. PLoS One, 2021, 16(9), e0256602. doi: 10.1371/journal.pone.0256602 PMID: 34492069
Chou, R.C.; Kane, M.; Ghimire, S.; Gautam, S.; Gui, J. Treatment for rheumatoid arthritis and risk of Alzheimers disease: A nested case/control analysis. CNS Drugs, 2016, 30(11), 1111-1120. doi: 10.1007/s40263-016-0374-z PMID: 27470609
Zhou, M.; Xu, R.; Kaelber, D.C.; Gurney, M.E. Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimers disease in patients with rheumatoid arthritis and psoriasis. PLoS One, 2020, 15(3), e0229819. doi: 10.1371/journal.pone.0229819 PMID: 32203525
Zheng, C.; Fillmore, N.R.; Ramos-Cejudo, J.; Brophy, M.; Osorio, R.; Gurney, M.E.; Qiu, W.Q.; Au, R.; Perry, G.; Dubreuil, M.; Chen, S.G.; Qi, X.; Davis, P.B.; Do, N.; Xu, R. Potential long-term effect of tumor necrosis factor inhibitors on dementia risk: A propensity score matched retrospective cohort study in US veterans. Alzheimers Dement., 2022, 18(6), 1248-1259. doi: 10.1002/alz.12465 PMID: 34569707
Newby, D.; Prieto-Alhambra, D.; Duarte-Salles, T.; Ansell, D.; Pedersen, L.; van der Lei, J.; Mosseveld, M.; Rijnbeek, P.; James, G.; Alexander, M.; Egger, P.; Podhorna, J.; Stewart, R.; Perera, G.; Avillach, P.; Grosdidier, S.; Lovestone, S.; Nevado-Holgado, A.J. Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: A multi-national multi-database case-control study. Alzheimers Res. Ther., 2020, 12(1), 38. doi: 10.1186/s13195-020-00606-5 PMID: 32252806
Watad, A.; McGonagle, D.; Anis, S.; Carmeli, R.; Cohen, A.D.; Tsur, A.M.; Ben-Shabat, N.; Luigi Bragazzi, N.; Lidar, M.; Amital, H. TNF inhibitors have a protective role in the risk of dementia in patients with ankylosing spondylitis: Results from a nationwide study. Pharmacol. Res., 2022, 182, 106325. doi: 10.1016/j.phrs.2022.106325 PMID: 35752359
Peter, I.; Dubinsky, M.; Bressman, S.; Park, A.; Lu, C.; Chen, N.; Wang, A. Antitumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease. JAMA Neurol., 2018, 75(8), 939-946. doi: 10.1001/jamaneurol.2018.0605 PMID: 29710331
Kern, D.M.; Lovestone, S.; Cepeda, M.S. Treatment with TNF-α inhibitors versus methotrexate and the association with dementia and Alzheimers disease. Alzheimers Dement., 2021, 7(1), e12163. doi: 10.1002/trc2.12163
Desai, R.J.; Varma, V.R.; Gerhard, T.; Segal, J.; Mahesri, M.; Chin, K.; Horton, D.B.; Kim, S.C.; Schneeweiss, S.; Thambisetty, M. Comparative risk of Alzheimer disease and related dementia among Medicare beneficiaries with Rheumatoid Arthritis treated with targeted disease/modifying antirheumatic agents. JAMA Netw. Open, 2022, 5(4), e226567. doi: 10.1001/jamanetworkopen.2022.6567 PMID: 35394510
Fardet, L.; Nazareth, I.; Petersen, I. Chronic hydroxychloroquine/chloroquine exposure for connective tissue diseases and risk of Alzheimers disease: A population-based cohort study. Ann. Rheum. Dis., 2019, 78(2) , 279.2-282. doi: 10.1136/annrheumdis-2018-214016 PMID: 30185414
Lai, S.W.; Kuo, Y.H.; Liao, K.F. Chronic hydroxychloroquine exposure and the risk of Alzheimers disease. Ann. Rheum. Dis., 2021, 80(7), e105. doi: 10.1136/annrheumdis-2019-216173 PMID: 31434638
Varma, V.R.; Desai, R.J.; Navakkode, S.; Wong, L.W.; Anerillas, C.; Loeffler, T.; Schilcher, I.; Mahesri, M.; Chin, K.; Horton, D.B.; Kim, S.C.; Gerhard, T.; Segal, J.B.; Schneeweiss, S.; Gorospe, M.; Sajikumar, S.; Thambisetty, M. Hydroxychloroquine lowers Alzheimers disease and related dementias risk and rescues molecular phenotypes related to Alzheimers disease. Mol. Psychiatry, 2023, 28(3), 1312-1326. doi: 10.1038/s41380-022-01912-0 PMID: 36577843
Mathieu, S.; Couderc, M.; Pereira, B.; Dubost, J.J.; Malochet-Guinamand, S.; Tournadre, A.; Soubrier, M.; Moisset, X. Prevalence of migraine and neuropathic pain in rheumatic diseases. J. Clin. Med., 2020, 9(6), 1890. doi: 10.3390/jcm9061890 PMID: 32560321
Wu, L.; Xu, Q.; Zhou, M.; Chen, Y.; Jiang, C.; Jiang, Y.; Lin, Y.; He, Q.; Zhao, L.; Dong, Y.; Liu, J.; Chen, W. Plasma miR-153 and miR-223 levels as potential biomarkers in Parkinsons disease. Front. Neurosci., 2022, 16, 865139. doi: 10.3389/fnins.2022.865139 PMID: 35655754
Li, D.; Yang, H.; Ma, J.; Luo, S.; Chen, S.; Gu, Q. MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinsons disease by targeting Nlrp3. Hum. Cell, 2018, 31(2), 106-115. doi: 10.1007/s13577-017-0187-5 PMID: 29274035
Taglialatela, G.; Rastellini, C.; Cicalese, L. Reduced incidence of dementia in solid organ transplant patients treated with calcineurin inhibitors. J. Alzheimers Dis., 2015, 47(2), 329-333. doi: 10.3233/JAD-150065 PMID: 26401556
Bukhbinder, A.S.; Ling, Y.; Hasan, O.; Jiang, X.; Kim, Y.; Phelps, K.N.; Schmandt, R.E.; Amran, A.; Coburn, R.; Ramesh, S.; Xiao, Q.; Schulz, P.E. Risk of Alzheimers disease following influenza vaccination: A claims-based cohort study using propensity score matching. J. Alzheimers Dis., 2022, 88(3), 1061-1074. doi: 10.3233/JAD-220361 PMID: 35723106
Klinger, D.; Hill, B.L.; Barda, N.; Halperin, E.; Gofrit, O.N.; Greenblatt, C.L.; Rappoport, N.; Linial, M.; Bercovier, H. Bladder cancer immunotherapy by BCG is associated with a significantly reduced risk of Alzheimers disease and Parkinsons disease. Vaccines,, 2021, 9(5), 491. doi: 10.3390/vaccines9050491 PMID: 34064775
Al-kuraishy, H.M.; Al-Gareeb, A.I.; Saad, H.M.; Batiha, G.E.S. Long-term use of metformin and Alzheimers disease: Beneficial or detrimental effects. Inflammopharmacology, 2023, 31(3), 1107-1115. doi: 10.1007/s10787-023-01163-7 PMID: 36849855
McGeer, P.L.; Rogers, J.; McGeer, E.G. Inflammation, anti-inflammatory agents and Alzheimer disease: The last 12 years. J. Alzheimers Dis., 2006, 9(s3)(Suppl.), 271-276. doi: 10.3233/JAD-2006-9S330 PMID: 16914866
Launer, L.J. Nonsteroidal anti-inflammatory drug use and the risk for Alzheimers disease: dissecting the epidemiological evidence. Drugs, 2003, 63(8), 731-739. doi: 10.2165/00003495-200363080-00001 PMID: 12662122
Daniels, M.J.D.; Rivers-Auty, J.; Schilling, T.; Spencer, N.G.; Watremez, W.; Fasolino, V.; Booth, S.J.; White, C.S.; Baldwin, A.G.; Freeman, S.; Wong, R.; Latta, C.; Yu, S.; Jackson, J.; Fischer, N.; Koziel, V.; Pillot, T.; Bagnall, J.; Allan, S.M.; Paszek, P.; Galea, J.; Harte, M.K.; Eder, C.; Lawrence, C.B.; Brough, D. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimers disease in rodent models. Nat. Commun., 2016, 7(1), 12504. doi: 10.1038/ncomms12504 PMID: 27509875
Annadurai, N.; De Sanctis, J.B.; Hajdúch, M.; Das, V. Tau secretion and propagation: Perspectives for potential preventive interventions in Alzheimers disease and other tauopathies. Exp. Neurol., 2021, 343, 113756. doi: 10.1016/j.expneurol.2021.113756 PMID: 33989658
Annadurai, N.; Malina, L.; Malohlava, J.; Hajdúch, M.; Das, V. Tau R2 and R3 are essential regions for tau aggregation, seeding and propagation. Biochimie, 2022, 200, 79-86. doi: 10.1016/j.biochi.2022.05.013 PMID: 35623497
Annadurai, N.; Malina, L.; Salmona, M.; Diomede, L.; Bastone, A.; Cagnotto, A.; Romeo, M.; rejber, M.; Berka, K.; Otyepka, M.; Hajdúch, M.; Das, V. Antitumour drugs targeting tau R3 VQIVYK and Cys322 prevent seeding of endogenous tau aggregates by exogenous seeds. FEBS J., 2022, 289(7), 1929-1949. doi: 10.1111/febs.16270 PMID: 34743390
Annadurai, N.; Hrubý, J.; Kubíčková, A.; Malina, L.; Hajdúch, M.; Das, V. Time- and dose-dependent seeding tendency of exogenous tau R2 and R3 aggregates in cells. Biochem. Biophys. Res. Commun., 2023, 653, 102-105. doi: 10.1016/j.bbrc.2023.02.057 PMID: 36863211
Ferretti, M.T.; Allard, S.; Partridge, V.; Ducatenzeiler, A.; Cuello, A.C. Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimers disease-like amyloid pathology. J. Neuroinflammation, 2012, 9(1), 62. doi: 10.1186/1742-2094-9-62 PMID: 22472085
Parashos, S.A.; Luo, S.; Biglan, K.M.; Bodis-Wollner, I.; He, B.; Liang, G.S.; Ross, G.W.; Tilley, B.C.; Shulman, L.M. Measuring disease progression in early Parkinson disease. JAMA Neurol., 2014, 71(6), 710-716. doi: 10.1001/jamaneurol.2014.391 PMID: 24711047
Nassar, N.N.; Al-Shorbagy, M.Y.; Arab, H.H.; Abdallah, D.M. Saxagliptin: A novel antiparkinsonian approach. Neuropharmacology, 2015, 89, 308-317. doi: 10.1016/j.neuropharm.2014.10.007 PMID: 25446674
Chen, S.; Zhou, M.; Sun, J.; Guo, A.; Fernando, R.L.; Chen, Y.; Peng, P.; Zhao, G.; Deng, Y. DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling. Neuropharmacology, 2019, 157, 107668. doi: 10.1016/j.neuropharm.2019.107668 PMID: 31199957
Yu, H.; Sun, T.; He, X.; Wang, Z.; Zhao, K.; An, J.; Wen, L.; Li, J.Y.; Li, W.; Feng, J. Association between Parkinsons disease and diabetes mellitus: From epidemiology, pathophysiology and prevention to treatment. Aging Dis., 2022, 13(6), 1591-1605. doi: 10.14336/AD.2022.0325 PMID: 36465171
Landreth, G.; Jiang, Q.; Mandrekar, S.; Heneka, M. PPARγ agonists as therapeutics for the treatment of Alzheimers disease. Neurotherapeutics, 2008, 5(3), 481-489. doi: 10.1016/j.nurt.2008.05.003 PMID: 18625459
Watson, G.S.; Cholerton, B.A.; Reger, M.A.; Baker, L.D.; Plymate, S.R.; Asthana, S.; Fishel, M.A.; Kulstad, J.J.; Green, P.S.; Cook, D.G.; Kahn, S.E.; Keeling, M.L.; Craft, S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study. Am. J. Geriatr. Psychiatry, 2005, 13(11), 950-958. doi: 10.1176/appi.ajgp.13.11.950 PMID: 16286438
Risner, M.E.; Saunders, A.M.; Altman, J F B.; Ormandy, G.C.; Craft, S.; Foley, I.M.; Zvartau-Hind, M.E.; Hosford, D.A.; Roses, A.D. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimers disease. Pharmacogenomics J., 2006, 6(4), 246-254. doi: 10.1038/sj.tpj.6500369 PMID: 16446752
Alhowail, A.; Alsikhan, R.; Alsaud, M.; Aldubayan, M.; Rabbani, S.I. Protective effects of pioglitazone on cognitive impairment and the underlying mechanisms: A review of literature. Drug Des. Devel. Ther., 2022, 16, 2919-2931. doi: 10.2147/DDDT.S367229 PMID: 36068789
Zhou, Y.; Chen, Y.; Xu, C.; Zhang, H.; Lin, C. TLR4 targeting as a promising therapeutic strategy for Alzheimer disease treatment. Front. Neurosci., 2020, 14, 602508. doi: 10.3389/fnins.2020.602508 PMID: 33390886
Cui, W.; Sun, C.; Ma, Y.; Wang, S.; Wang, X.; Zhang, Y. Inhibition of TLR4 Induces M2 microglial polarization and provides neuroprotection via the NLRP3 inflammasome in Alzheimers disease. Front. Neurosci., 2020, 14, 444. doi: 10.3389/fnins.2020.00444 PMID: 32508567
Jin, X.; Liu, M.Y.; Zhang, D.F.; Zhong, X.; Du, K.; Qian, P.; Yao, W.F.; Gao, H.; Wei, M.J. Baicalin mitigates cognitive impairment and protects neurons from microglia-mediated neuroinflammation via suppressing NLRP 3 inflammasomes and TLR 4/NFκB signaling pathway. CNS Neurosci. Ther., 2019, 25(5), 575-590. doi: 10.1111/cns.13086 PMID: 30676698
Shi, S.; Liang, D.; Chen, Y.; Xie, Y.; Wang, Y.; Wang, L.; Wang, Z.; Qiao, Z. Gx-50 reduces β-amyloid-induced TNF-α IL-1β NO, and PGE2 expression and inhibits NF-κB signaling in a mouse model of Alzheimers disease. Eur. J. Immunol., 2016, 46(3), 665-676. doi: 10.1002/eji.201545855 PMID: 26643273
Kim, C.; Spencer, B.; Rockenstein, E.; Yamakado, H.; Mante, M.; Adame, A.; Fields, J.A.; Masliah, D.; Iba, M.; Lee, H.J.; Rissman, R.A.; Lee, S.J.; Masliah, E. Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation. Mol. Neurodegener., 2018, 13(1), 43. doi: 10.1186/s13024-018-0276-2 PMID: 30092810
Lee, H.; Jeon, S.G.; Kim, J.; Kang, R.J.; Kim, S.M.; Han, K.M.; Park, H.; Kim, K.; Sung, Y.M.; Nam, H.Y.; Koh, Y.H.; Song, M.; Suk, K.; Hoe, H.S. Ibrutinib modulates Aβ/tau pathology, neuroinflammation, and cognitive function in mouse models of Alzheimers disease. Aging Cell, 2021, 20(3), e13332. doi: 10.1111/acel.13332 PMID: 33709472
He, P.; Cheng, X.; Staufenbiel, M.; Li, R.; Shen, Y. Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β-secretase in a mouse model of Alzheimers disease. PLoS One, 2013, 8(2), e55091. doi: 10.1371/journal.pone.0055091 PMID: 23405115
Decourt, B.; Drumm-Gurnee, D.; Wilson, J.; Jacobson, S.; Belden, C.; Sirrel, S.; Ahmadi, M.; Shill, H.; Powell, J.; Walker, A.; Gonzales, A.; Macias, M.; Sabbagh, M.N. Poor safety and tolerability hamper reaching a potentially therapeutic dose in the use of thalidomide for Alzheimers disease: Results from a double-blind, placebo-controlled trial. Curr. Alzheimer Res., 2017, 14(4), 403-411. doi: 10.2174/1567205014666170117141330 PMID: 28124585
Decourt, B.; Wilson, J.; Ritter, A.; Dardis, C.; DiFilippo, F.; Zhuang, X.; Cordes, D.; Lee, G.; Fulkerson, N.; St Rose, T.; Hartley, K.; Sabbagh, M. MCLENA-1: A phase ii clinical trial for the assessment of safety, tolerability, and efficacy of lenalidomide in patients with mild cognitive impairment due to Alzheimers disease. Open Access J. Clin. Trials, 2020, 12, 1-13. doi: 10.2147/OAJCT.S221914 PMID: 32123490
Palmas, M.F.; Ena, A.; Burgaletto, C.; Casu, M.A.; Cantarella, G.; Carboni, E.; Etzi, M.; De Simone, A.; Fusco, G.; Cardia, M.C.; Lai, F.; Picci, L.; Tweedie, D.; Scerba, M.T.; Coroneo, V.; Bernardini, R.; Greig, N.H.; Pisanu, A.; Carta, A.R. Repurposing pomalidomide as a neuroprotective drug: Efficacy in an alpha-synuclein-based model of parkinsons disease. Neurotherapeutics, 2022, 19(1), 305-324. doi: 10.1007/s13311-022-01182-2 PMID: 35072912
Singh, S.; Ganguly, U.; Pal, S.; Chandan, G.; Thakur, R.; Saini, R.V.; Chakrabarti, S.S.; Agrawal, B.K.; Chakrabarti, S. Protective effects of cyclosporine A on neurodegeneration and motor impairment in rotenone-induced experimental models of Parkinsons disease. Eur. J. Pharmacol., 2022, 929, 175129. doi: 10.1016/j.ejphar.2022.175129 PMID: 35777442
Van der Perren, A.; Macchi, F.; Toelen, J.; Carlon, M.S.; Maris, M.; de Loor, H.; Kuypers, D.R.J.; Gijsbers, R.; Van den Haute, C.; Debyser, Z.; Baekelandt, V. FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinsons disease. Neurobiol. Aging, 2015, 36(3), 1559-1568. doi: 10.1016/j.neurobiolaging.2015.01.014 PMID: 25660193
Köylü, A.; Altunkaynak, B.Z.; Delibaş, B. Effects of tacrolimus on c-fos in hippocampus and memory performances in streptozotocin model of Alzheimers disease of rats. Turk. J. Med. Sci., 2021, 51(4), 2159-2166. doi: 10.3906/sag-2008-291 PMID: 33754647
Kumar, A.; Singh, N. Calcineurin inhibition and protein kinase a activation limits cognitive dysfunction and histopathological damage in a model of dementia of the Alzheimers type. Curr. Neurovasc. Res., 2018, 15(3), 234-245. doi: 10.2174/1567202615666180813125125 PMID: 30101704
Lai, W.D.; Wang, S.; You, W.T.; Chen, S.J.; Wen, J.J.; Yuan, C.R.; Zheng, M.J.; Jin, Y.; Yu, J.; Wen, C.P. Sinomenine regulates immune cell subsets: Potential neuro-immune intervene for precise treatment of chronic pain. Front. Cell Dev. Biol., 2022, 10, 1041006. doi: 10.3389/fcell.2022.1041006 PMID: 36619869
Alam, J.; Blackburn, K.; Patrick, D. Neflamapimod: Clinical phase 2b-ready oral small molecule inhibitor of p38α to reverse synaptic dysfunction in early Alzheimers disease. J. Prev. Alzheimers Dis., 2017, 4(4), 273-278. PMID: 29181493
Prins, N.D.; Harrison, J.E.; Chu, H.M.; Blackburn, K.; Alam, J.J.; Scheltens, P. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimers disease. Alzheimers Res. Ther., 2021, 13(1), 106. doi: 10.1186/s13195-021-00843-2 PMID: 34044875
Rothhammer, V.; Kenison, J.E.; Li, Z.; Tjon, E.; Takenaka, M.C.; Chao, C.C.; Alves de Lima, K.; Borucki, D.M.; Kaye, J.; Quintana, F.J. Aryl hydrocarbon receptor activation in astrocytes by laquinimod ameliorates autoimmune inflammation in the CNS. Neurol. Neuroimmunol. Neuroinflamm., 2021, 8(2), e946. doi: 10.1212/NXI.0000000000000946 PMID: 33408169
Srivastava, S.; Rajopadhye, R.; Dey, M.; Singh, R.K. Inhibition of MK2 kinase as a potential therapeutic target to control neuroinflammation in Alzheimers disease. Expert Opin. Ther. Targets, 2021, 25(4), 243-247. doi: 10.1080/14728222.2021.1924151 PMID: 33909536
Roy, S.M.; Minasov, G.; Arancio, O.; Chico, L.W.; Van Eldik, L.J.; Anderson, W.F.; Pelletier, J.C.; Watterson, D.M. A selective and brain penetrant p38αMAPK inhibitor candidate for neurologic and neuropsychiatric disorders that attenuates neuroinflammation and cognitive dysfunction. J. Med. Chem., 2019, 62(11), 5298-5311. doi: 10.1021/acs.jmedchem.9b00058 PMID: 30978288
Martínez, G.; Mijares, M.R.; De Sanctis, J.B. Effects of flavonoids and its derivatives on immune cell responses. Recent Pat. Inflamm. Allergy Drug Discov., 2019, 13(2), 84-104. doi: 10.2174/1872213X13666190426164124 PMID: 31814545
Ping, Z.; Xiaomu, W.; Xufang, X.; Liang, S. Vinpocetine regulates levels of circulating TLRs in Parkinsons disease patients. Neurol. Sci., 2019, 40(1), 113-120. doi: 10.1007/s10072-018-3592-y PMID: 30315378
Cui, B.; Guo, X.; You, Y.; Fu, R. Farrerol attenuates MPP+induced inflammatory response by TLR4 signaling in a microglia cell line. Phytother. Res., 2019, 33(4), 1134-1141. doi: 10.1002/ptr.6307 PMID: 30734970
Yang, Y.L.; Cheng, X.; Li, W.H.; Liu, M.; Wang, Y.H.; Du, G.H. Kaempferol attenuates LPS-induced striatum injury in mice involving anti-neuroinflammation, maintaining BBB integrity, and down-regulating the HMGB1/TLR4 pathway. Int. J. Mol. Sci., 2019, 20(3), 491. doi: 10.3390/ijms20030491 PMID: 30678325
Yang, L.; Zhou, R.; Tong, Y.; Chen, P.; Shen, Y.; Miao, S.; Liu, X. Neuroprotection by dihydrotestosterone in LPS-induced neuroinflammation. Neurobiol. Dis., 2020, 140, 104814. doi: 10.1016/j.nbd.2020.104814 PMID: 32087283
Haddadi, R.; Nayebi, A.M.; Eyvari, B.S. RETRACTED: Silymarin prevents apoptosis through inhibiting the Bax/caspase-3 expression and suppresses toll like receptor-4 pathway in the SNc of 6-OHDA intoxicated rats. Biomed. Pharmacother., 2018, 104, 127-136. doi: 10.1016/j.biopha.2018.05.020 PMID: 29772432
Su, Q.; Ng, W.L.; Goh, S.Y.; Gulam, M.Y.; Wang, L.F.; Tan, E.K.; Ahn, M.; Chao, Y.X. Targeting the inflammasome in Parkinsons disease. Front. Aging Neurosci., 2022, 14, 957705. doi: 10.3389/fnagi.2022.957705 PMID: 36313019
Yang, Y.; Guo, L.; Wang, J.; Li, W.; Zhou, X.; Zhang, C.; Han, C. Arglabin regulates microglia polarization to relieve neuroinflammation in Alzheimers disease. J. Biochem. Mol. Toxicol., 2022, 36(6), e23045. doi: 10.1002/jbt.23045 PMID: 35289014
Tong, B.C.K.; Huang, A.S.; Wu, A.J.; Iyaswamy, A.; Ho, O.K.Y.; Kong, A.H.Y.; Sreenivasmurthy, S.G.; Zhu, Z.; Su, C.; Liu, J.; Song, J.; Li, M.; Cheung, K.H. Tetrandrine ameliorates cognitive deficits and mitigates tau aggregation in cell and animal models of tauopathies. J. Biomed. Sci., 2022, 29(1), 85. doi: 10.1186/s12929-022-00871-6 PMID: 36273169
Velagapudi, R.; Aderogba, M.; Olajide, O.A. Tiliroside, a dietary glycosidic flavonoid, inhibits TRAF-6/NF-κB/p38-mediated neuroinflammation in activated BV2 microglia. Biochim. Biophys. Acta, Gen. Subj., 2014, 1840(12), 3311-3319. doi: 10.1016/j.bbagen.2014.08.008 PMID: 25152356
Wu, Q.; Naeem, A.; Zou, J.; Yu, C.; Wang, Y.; Chen, J.; Ping, Y. Isolation of phenolic compounds from raspberry based on molecular imprinting techniques and investigation of their anti-alzheimers disease properties. Molecules, 2022, 27(20), 6893. doi: 10.3390/molecules27206893 PMID: 36296486
Rezai-Zadeh, K.; Ehrhart, J.; Bai, Y.; Sanberg, P.R.; Bickford, P.; Tan, J.; Shytle, R.D. Apigenin and luteolin modulate microglial activation via inhibition of STAT1-induced CD40 expression. J. Neuroinflammation, 2008, 5(1), 41. doi: 10.1186/1742-2094-5-41 PMID: 18817573
Liu, R.; Zhang, T.; Yang, H.; Lan, X.; Ying, J.; Du, G. The flavonoid apigenin protects brain neurovascular coupling against amyloid-β₂₅₋₃₅-induced toxicity in mice. J. Alzheimers Dis., 2011, 24(1), 85-100. doi: 10.3233/JAD-2010-101593 PMID: 21297270
Kang, C.H.; Choi, Y.H.; Moon, S.K.; Kim, W.J.; Kim, G.Y. Quercetin inhibits lipopolysaccharide-induced nitric oxide production in BV2 microglial cells by suppressing the NF-κB pathway and activating the Nrf2-dependent HO-1 pathway. Int. Immunopharmacol., 2013, 17(3), 808-813. doi: 10.1016/j.intimp.2013.09.009 PMID: 24076371
Wightman, E.L.; Haskell, C.F.; Forster, J.S.; Veasey, R.C.; Kennedy, D.O. Epigallocatechin gallate, cerebral blood flow parameters, cognitive performance and mood in healthy humans: a double-blind, placebo-controlled, crossover investigation. Hum. Psychopharmacol., 2012, 27(2), 177-186. doi: 10.1002/hup.1263 PMID: 22389082
Olajide, O.A.; Sarker, S.D. Alzheimers disease: Natural products as inhibitors of neuroinflammation. Inflammopharmacology, 2020, 28(6), 1439-1455. doi: 10.1007/s10787-020-00751-1 PMID: 32930914
Moussa, C.; Hebron, M.; Huang, X.; Ahn, J.; Rissman, R.A.; Aisen, P.S.; Turner, R.S. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimers disease. J. Neuroinflammation, 2017, 14(1), 1. doi: 10.1186/s12974-016-0779-0 PMID: 28086917
Porro, C.; Cianciulli, A.; Trotta, T.; Lofrumento, D.D.; Panaro, M.A. Curcumin regulates anti-inflammatory responses by JAK/STAT/SOCS signaling pathway in bv-2 microglial cells. Biology,, 2019, 8(3), 51. doi: 10.3390/biology8030051 PMID: 31252572
Sorrenti, V.; Contarini, G.; Sut, S.; DallAcqua, S.; Confortin, F.; Pagetta, A.; Giusti, P.; Zusso, M. Curcumin prevents acute neuroinflammation and long-term memory impairment induced by systemic lipopolysaccharide in mice. Front. Pharmacol., 2018, 9, 183. doi: 10.3389/fphar.2018.00183 PMID: 29556196
Sundaram, J.R.; Poore, C.P.; Sulaimee, N.H.B.; Pareek, T.; Cheong, W.F.; Wenk, M.R.; Pant, H.C.; Frautschy, S.A.; Low, C.M.; Kesavapany, S. Curcumin ameliorates neuroinflammation, neurodegeneration, and memory deficits in p25 transgenic mouse model that bears hallmarks of alzheimers disease. J. Alzheimers Dis., 2017, 60(4), 1429-1442. doi: 10.3233/JAD-170093 PMID: 29036814
Ringman, J.M.; Frautschy, S.A.; Teng, E.; Begum, A.N.; Bardens, J.; Beigi, M.; Gylys, K.H.; Badmaev, V.; Heath, D.D.; Apostolova, L.G.; Porter, V.; Vanek, Z.; Marshall, G.A.; Hellemann, G.; Sugar, C.; Masterman, D.L.; Montine, T.J.; Cummings, J.L.; Cole, G.M. Oral curcumin for Alzheimers disease: Tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res. Ther., 2012, 4(5), 43. doi: 10.1186/alzrt146 PMID: 23107780
Cox, K.H.M.; Pipingas, A.; Scholey, A.B. Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J. Psychopharmacol., 2015, 29(5), 642-651. doi: 10.1177/0269881114552744 PMID: 25277322
Small, G.W.; Siddarth, P.; Li, Z.; Miller, K.J.; Ercoli, L.; Emerson, N.D.; Martinez, J.; Wong, K.P.; Liu, J.; Merrill, D.A.; Chen, S.T.; Henning, S.M.; Satyamurthy, N.; Huang, S.C.; Heber, D.; Barrio, J.R. Memory and brain amyloid and tau effects of a bioavailable form of curcumin in non-demented adults: A double-blind, placebo-controlled 18-month trial. Am. J. Geriatr. Psychiatry, 2018, 26(3), 266-277. doi: 10.1016/j.jagp.2017.10.010 PMID: 29246725
Khare, P.; Datusalia, A.K.; Sharma, S.S. Parthenolide, an NF-κB Inhibitor ameliorates diabetes-induced behavioural deficit, neurotransmitter imbalance and neuroinflammation in type 2 diabetes rat model. Neuromol. Med., 2017, 19(1), 101-112. doi: 10.1007/s12017-016-8434-6 PMID: 27553015
Qiang, W.; Cai, W.; Yang, Q.; Yang, L.; Dai, Y.; Zhao, Z.; Yin, J.; Li, Y.; Li, Q.; Wang, Y.; Weng, X.; Zhang, D.; Chen, Y.; Zhu, X.; Artemisinin, B.; Artemisinin, B. Improves learning and memory impairment in AD dementia mice by suppressing neuroinflammation. Neuroscience, 2018, 395, 1-12. doi: 10.1016/j.neuroscience.2018.10.041 PMID: 30399421
Zhou, J.M.; Gu, S.S.; Mei, W.H.; Zhou, J.; Wang, Z.Z.; Xiao, W. Ginkgolides and bilobalide protect BV2 microglia cells against OGD/reoxygenation injury by inhibiting TLR2/4 signaling pathways. Cell Stress Chaperones, 2016, 21(6), 1037-1053. doi: 10.1007/s12192-016-0728-y PMID: 27562518
de Oliveira, M.R. The dietary components carnosic acid and carnosol as neuroprotective agents: A Mechanistic View. Mol. Neurobiol., 2016, 53(9), 6155-6168. doi: 10.1007/s12035-015-9519-1 PMID: 26553346
Velagapudi, R.; Kumar, A.; Bhatia, H.S.; El-Bakoush, A.; Lepiarz, I.; Fiebich, B.L.; Olajide, O.A. Inhibition of neuroinflammation by thymoquinone requires activation of Nrf2/ARE signalling. Int. Immunopharmacol., 2017, 48, 17-29. doi: 10.1016/j.intimp.2017.04.018 PMID: 28458100
Yang, W.; Qiu, X.; Wu, Q.; Chang, F.; Zhou, T.; Zhou, M.; Pei, J. Active constituents of saffron (Crocus sativus L.) and their prospects in treating neurodegenerative diseases. (Review). Exp. Ther. Med., 2023, 25(5), 235. doi: 10.3892/etm.2023.11934 PMID: 37114174
Fu, M.; Liang, X.; Zhang, X.; Yang, M.; Ye, Q.; Qi, Y.; Liu, H.; Zhang, X. Astaxanthin delays brain aging in senescence-accelerated mouse prone 10: inducing autophagy as a potential mechanism. Nutr. Neurosci., 2023, 26(5), 445-455. doi: 10.1080/1028415X.2022.2055376 PMID: 35385370
Lin, C.H.; Chou, C.C.; Lee, Y.H.; Hung, C.C. Curcumin facilitates aryl hydrocarbon receptor activation to ameliorate inflammatory astrogliosis. Molecules, 2022, 27(8), 2507. doi: 10.3390/molecules27082507 PMID: 35458704
Hong, S.; Beja-Glasser, V.F.; Nfonoyim, B.M.; Frouin, A.; Li, S.; Ramakrishnan, S.; Merry, K.M.; Shi, Q.; Rosenthal, A.; Barres, B.A.; Lemere, C.A.; Selkoe, D.J.; Stevens, B. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science, 2016, 352(6286), 712-716. doi: 10.1126/science.aad8373 PMID: 27033548
Pittock, S.J.; Berthele, A.; Fujihara, K.; Kim, H.J.; Levy, M.; Palace, J.; Nakashima, I.; Terzi, M.; Totolyan, N.; Viswanathan, S.; Wang, K.C.; Pace, A.; Fujita, K.P.; Armstrong, R.; Wingerchuk, D.M. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N. Engl. J. Med., 2019, 381(7), 614-625. doi: 10.1056/NEJMoa1900866 PMID: 31050279
Lamers, C.; Mastellos, D.C.; Ricklin, D.; Lambris, J.D. Compstatins: The dawn of clinical C3-targeted complement inhibition. Trends Pharmacol. Sci., 2022, 43(8), 629-640. doi: 10.1016/j.tips.2022.01.004 PMID: 35090732
Lansita, J.A.; Mease, K.M.; Qiu, H.; Yednock, T.; Sankaranarayanan, S.; Kramer, S. Nonclinical development of ANX005: A humanized anti-C1q antibody for treatment of autoimmune and neurodegenerative diseases. Int. J. Toxicol., 2017, 36(6), 449-462. doi: 10.1177/1091581817740873 PMID: 29202623
Qi, Y.; Klyubin, I.; Cuello, A.C.; Rowan, M.J. NLRP3-dependent synaptic plasticity deficit in an Alzheimers disease amyloidosis model in vivo. Neurobiol. Dis., 2018, 114, 24-30. doi: 10.1016/j.nbd.2018.02.016 PMID: 29477641
Ben-Menachem-Zidon, O.; Ben-Menahem, Y.; Ben-Hur, T.; Yirmiya, R. Intra-hippocampal transplantation of neural precursor cells with transgenic over-expression of IL-1 receptor antagonist rescues memory and neurogenesis impairments in an Alzheimers disease model. Neuropsychopharmacology, 2014, 39(2), 401-414. doi: 10.1038/npp.2013.208 PMID: 23954849
Cavanagh, C.; Tse, Y.C.; Nguyen, H.B.; Krantic, S.; Breitner, J.C.S.; Quirion, R.; Wong, T.P. Inhibiting tumor necrosis factor-α before amyloidosis prevents synaptic deficits in an Alzheimers disease model. Neurobiol. Aging, 2016, 47, 41-49. doi: 10.1016/j.neurobiolaging.2016.07.009 PMID: 27552480
Cavanagh, C.; Wong, T.P. Preventing synaptic deficits in Alzheimers disease by inhibiting tumor necrosis factor alpha signaling. IBRO Rep., 2018, 4, 18-21. doi: 10.1016/j.ibror.2018.01.003 PMID: 30135948
Li, Y.; Fan, H.; Ni, M.; Zhang, W.; Fang, F.; Sun, J.; Lyu, P.; Ma, P. Etanercept reduces neuron injury and neuroinflammation via inactivating c-Jun N-terminal kinase and nuclear factor-κB Pathways in Alzheimers disease: An in vitro and in vivo investigation. Neuroscience, 2022, 484, 140-150. doi: 10.1016/j.neuroscience.2021.11.001 PMID: 35058089
Tobinick, E.; Gross, H.; Weinberger, A.; Cohen, H. TNF-alpha modulation for treatment of Alzheimers disease: A 6-month pilot study. MedGenMed, 2006, 8(2), 25. PMID: 16926764
Tobinick, E.L.; Gross, H. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimers disease. BMC Neurol., 2008, 8, 27. doi: 10.1186/1471-2377-8-27
Butchart, J.; Brook, L.; Hopkins, V.; Teeling, J.; Püntener, U.; Culliford, D.; Sharples, R.; Sharif, S.; McFarlane, B.; Raybould, R.; Thomas, R.; Passmore, P.; Perry, V.H.; Holmes, C. Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial. Neurology, 2015, 84(21), 2161-2168. doi: 10.1212/WNL.0000000000001617 PMID: 25934853
Tufan, A.N.; Holmes, C.; Tufan, F. Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trialAuthor Response. Neurology, 2015, 85(23) , 2083.2-2084. doi: 10.1212/01.wnl.0000475736.75775.25 PMID: 26644053
Torres-Acosta, N.; OKeefe, J.H.; OKeefe, E.L.; Isaacson, R.; Small, G. Therapeutic potential of TNF-α inhibition for Alzheimers disease prevention. J. Alzheimers Dis., 2020, 78(2), 619-626. doi: 10.3233/JAD-200711 PMID: 33016914
vom Berg, J.; Prokop, S.; Miller, K.R.; Obst, J.; Kälin, R.E.; Lopategui-Cabezas, I.; Wegner, A.; Mair, F.; Schipke, C.G.; Peters, O.; Winter, Y.; Becher, B.; Heppner, F.L. Inhibition of IL-12/IL-23 signaling reduces Alzheimers disease-like pathology and cognitive decline. Nat. Med., 2012, 18(12), 1812-1819. doi: 10.1038/nm.2965 PMID: 23178247
Pedrini, S.; Gupta, V.B.; Hone, E.; Doecke, J.; OBryant, S.; James, I.; Bush, A.I.; Rowe, C.C.; Villemagne, V.L.; Ames, D.; Masters, C.L.; Martins, R.N.; Savage, G.; Wilson, B.; Bourgeat, P.; Fripp, J.; Gibson, S.; Leroux, H.; McBride, S.; Salvado, O.; Fenech, M.; Francois, M.; Barnes, M.; Baker, J.; Barnham, K.; Bellingham, S.; Bomke, J.; Pejoska, S.B.; Buckley, R.; Cheng, L.; Collins, S.; Cooke, I.; Cyarto, E.; Darby, D.; Dore, V.; El-Sheikh, D.; Faux, N.; Fowler, C.; Harrington, K.; Hill, A.; Horne, M.; Jones, G.; Kamer, A.; Killeen, N.; Korrel, H.; Lamb, F.; Lautenschlager, N.; Lennon, K.; Li, Q-X.; Lim, Y.Y.; Louey, A.; Macaulay, L.; Mackintosh, L.; Maruff, P.; Mcilroy, A.; Nigro, J.; Perez, K.; Pertile, K.; Restrepo, C.; Cardoso, B.R.; Rembach, A.; Roberts, B.; Robertson, J.; Rumble, R.; Ryan, T.; Sach, J.; Silbert, B.; Thai, C.; Trounson, B.; Volitakis, I.; Vovos, M.; Ward, L.; Watt, A.; Williams, R.; Woodward, M.; Yates, P.; Ugarte, F.Y.; Zhang, P.; Bird, S.; Brown, B.; Burnham, S.; Chatterjee, P.; Cox, K.; Fernandez, S.; Fernando, B.; Gardener, S.; Laws, S.; Lim, F.; Lim, L.; Tegg, M.; Lucas, K.; Martins, G.; Porter, T.; Rainey-Smith, S.; Rodrigues, M.; Shen, K.K.; Sohrabi, H.; Taddei, K.; Taddei, T.; Tan, S.; Verdile, G.; Weinborn, M.; Farrow, M.; Frost, S.; Hanson, D.; Hor, M.; Kanagasingam, Y.; Leifert, W.; Lockett, L.; Riley, M.; Saunders, I.; Thomas, P. A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort. Sci. Rep., 2017, 7(1), 14057. doi: 10.1038/s41598-017-14020-9 PMID: 29070909
Eede, P.; Obst, J.; Benke, E.; Yvon-Durocher, G.; Richard, B.C.; Gimber, N.; Schmoranzer, J.; Böddrich, A.; Wanker, E.E.; Prokop, S.; Heppner, F.L. Interleukin-/23 deficiency differentially affects pathology in male and female Alzheimers disease-like mice. EMBO Rep., 2020, 21(3), e48530. doi: 10.15252/embr.201948530 PMID: 32003148
Porro, C.; Cianciulli, A.; Panaro, M.A. The Regulatory Role of IL-10 in neurodegenerative diseases. Biomolecules, 2020, 10(7), 1017. doi: 10.3390/biom10071017 PMID: 32659950
Fei, Z.; Pan, B.; Pei, R.; Chen, Z.; Du, X.; Cao, H.; Li, C. Efficacy and safety of blood derivatives therapy in Alzheimers disease: A systematic review and meta-analysis. Syst. Rev., 2022, 11(1), 256. doi: 10.1186/s13643-022-02115-y PMID: 36443888
Rinne, J.O.; Brooks, D.J.; Rossor, M.N.; Fox, N.C.; Bullock, R.; Klunk, W.E.; Mathis, C.A.; Blennow, K.; Barakos, J.; Okello, A.A. de LIano, S.R.M.; Liu, E.; Koller, M.; Gregg, K.M.; Schenk, D.; Black, R.; Grundman, M. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimers disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol., 2010, 9(4), 363-372. doi: 10.1016/S1474-4422(10)70043-0 PMID: 20189881
Vandenberghe, R.; Rinne, J.O.; Boada, M.; Katayama, S.; Scheltens, P.; Vellas, B.; Tuchman, M.; Gass, A.; Fiebach, J.B.; Hill, D.; Lobello, K.; Li, D.; McRae, T.; Lucas, P.; Evans, I.; Booth, K.; Luscan, G.; Wyman, B.T.; Hua, L.; Yang, L.; Brashear, H.R.; Black, R.S. Bapineuzumab for mild to moderate Alzheimers disease in two global, randomized, phase 3 trials. Alzheimers Res. Ther., 2016, 8(1), 18. doi: 10.1186/s13195-016-0189-7 PMID: 27176461
Delnomdedieu, M.; Duvvuri, S.; Li, D.J.; Atassi, N.; Lu, M.; Brashear, H.R.; Liu, E.; Ness, S.; Kupiec, J.W. First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimers disease. Alzheimers Res. Ther., 2016, 8(1), 12. doi: 10.1186/s13195-016-0177-y PMID: 26925577
Salloway, S.; Sperling, R.; Brashear, H.R. Phase 3 trials of solanezumab and bapineuzumab for Alzheimers disease. N. Engl. J. Med., 2014, 370(15), 1460. PMID: 24724181
SallowayS.SperlingR.FoxN.C.BlennowK.KlunkW.RaskindM.SabbaghM.HonigL.S.PorsteinssonA.P.FerrisS.ReichertM.KetterN.NejadnikB.GuenzlerV.MiloslavskyM.WangD.LuY.LullJ.TudorI.C.LiuE.GrundmanM.YuenE.BlackR.BrashearH.R.Bapineuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimers disease. N. Engl. J. Med., 2014, 370(4), 322-333. doi: 10.1056/NEJMoa1304839 PMID: 24450891
Honig, L.S.; Vellas, B.; Woodward, M.; Boada, M.; Bullock, R.; Borrie, M.; Hager, K.; Andreasen, N.; Scarpini, E.; Liu-Seifert, H.; Case, M.; Dean, R.A.; Hake, A.; Sundell, K.; Poole Hoffmann, V.; Carlson, C.; Khanna, R.; Mintun, M.; DeMattos, R.; Selzler, K.J.; Siemers, E. Trial of solanezumab for mild dementia due to alzheimers disease. N. Engl. J. Med., 2018, 378(4), 321-330. doi: 10.1056/NEJMoa1705971 PMID: 29365294
Salloway, S.; Farlow, M.; McDade, E.; Clifford, D.B.; Wang, G.; Llibre-Guerra, J.J.; Hitchcock, J.M.; Mills, S.L.; Santacruz, A.M.; Aschenbrenner, A.J.; Hassenstab, J.; Benzinger, T.L.S.; Gordon, B.A.; Fagan, A.M.; Coalier, K.A.; Cruchaga, C.; Goate, A.A.; Perrin, R.J.; Xiong, C.; Li, Y.; Morris, J.C.; Snider, B.J.; Mummery, C.; Surti, G.M.; Hannequin, D.; Wallon, D.; Berman, S.B.; Lah, J.J.; Jimenez-Velazquez, I.Z.; Roberson, E.D.; van Dyck, C.H.; Honig, L.S.; Sánchez-Valle, R.; Brooks, W.S.; Gauthier, S.; Galasko, D.R.; Masters, C.L.; Brosch, J.R.; Hsiung, G.Y.R.; Jayadev, S.; Formaglio, M.; Masellis, M.; Clarnette, R.; Pariente, J.; Dubois, B.; Pasquier, F.; Jack, C.R., Jr; Koeppe, R.; Snyder, P.J.; Aisen, P.S.; Thomas, R.G.; Berry, S.M.; Wendelberger, B.A.; Andersen, S.W.; Holdridge, K.C.; Mintun, M.A.; Yaari, R.; Sims, J.R.; Baudler, M.; Delmar, P.; Doody, R.S.; Fontoura, P.; Giacobino, C.; Kerchner, G.A.; Bateman, R.J.; Formaglio, M.; Mills, S.L.; Pariente, J.; van Dyck, C.H. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimers disease. Nat. Med., 2021, 27(7), 1187-1196. doi: 10.1038/s41591-021-01369-8 PMID: 34155411
Geerts, H.; Walker, M.; Rose, R.; Bergeler, S.; van der Graaf, P.H.; Schuck, E.; Koyama, A.; Yasuda, S.; Hussein, Z.; Reyderman, L.; Swanson, C.; Cabal, A. A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimers disease. CPT Pharmacometrics Syst. Pharmacol., 2023, 12(4), 444-461. doi: 10.1002/psp4.12912 PMID: 36632701
Hettmann, T.; Gillies, S.D.; Kleinschmidt, M.; Piechotta, A.; Makioka, K.; Lemere, C.A.; Schilling, S.; Rahfeld, J.U.; Lues, I. Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimers disease with reduced complement activation. Sci. Rep., 2020, 10(1), 3294. doi: 10.1038/s41598-020-60319-5 PMID: 32094456
Mintun, M.A.; Lo, A.C.; Duggan Evans, C.; Wessels, A.M.; Ardayfio, P.A.; Andersen, S.W.; Shcherbinin, S.; Sparks, J.; Sims, J.R.; Brys, M.; Apostolova, L.G.; Salloway, S.P.; Skovronsky, D.M. Donanemab in early Alzheimers disease. N. Engl. J. Med., 2021, 384(18), 1691-1704. doi: 10.1056/NEJMoa2100708 PMID: 33720637
Lowe, S.L.; Duggan Evans, C.; Shcherbinin, S.; Cheng, Y.J.; Willis, B.A.; Gueorguieva, I.; Lo, A.C.; Fleisher, A.S.; Dage, J.L.; Ardayfio, P.; Aguiar, G.; Ishibai, M.; Takaichi, G.; Chua, L.; Mullins, G.; Sims, J.R. Donanemab (LY3002813) Phase 1b study in alzheimers disease: Rapid and sustained reduction of brain amyloid measured by florbetapir F18 Imaging. J. Prev. Alzheimers Dis., 2021, 8(4), 414-424. PMID: 34585215
Gueorguieva, I.; Willis, B.A.; Chua, L.; Chow, K.; Ernest, C.S.; Shcherbinin, S.; Ardayfio, P.; Mullins, G.R.; Sims, J.R. Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimers disease. Clin. Pharmacol. Ther., 2023, 113(6), 1258-1267. doi: 10.1002/cpt.2875 PMID: 36805552
Sevigny, J.; Chiao, P.; Bussière, T.; Weinreb, P.H.; Williams, L.; Maier, M.; Dunstan, R.; Salloway, S.; Chen, T.; Ling, Y.; OGorman, J.; Qian, F.; Arastu, M.; Li, M.; Chollate, S.; Brennan, M.S.; Quintero-Monzon, O.; Scannevin, R.H.; Arnold, H.M.; Engber, T.; Rhodes, K.; Ferrero, J.; Hang, Y.; Mikulskis, A.; Grimm, J.; Hock, C.; Nitsch, R.M.; Sandrock, A. The antibody aducanumab reduces Aβ plaques in Alzheimers disease. Nature, 2016, 537(7618), 50-56. doi: 10.1038/nature19323 PMID: 27582220
Doroszkiewicz, J.; Mroczko, B. New possibilities in the therapeutic approach to Alzheimers disease. Int. J. Mol. Sci., 2022, 23(16), 8902. doi: 10.3390/ijms23168902 PMID: 36012193
Söderberg, L.; Johannesson, M.; Nygren, P.; Laudon, H.; Eriksson, F.; Osswald, G.; Möller, C.; Lannfelt, L. Lecanemab, aducanumab, and gantenerumab: Binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for alzheimers disease. Neurotherapeutics, 2023, 20(1), 195-206. doi: 10.1007/s13311-022-01308-6 PMID: 36253511
Brandt, N.J.; Wheeler, C.; Courtin, S.O. Navigating disease-modifying treatments for Alzheimers disease: Focusing on medications in phase 3 clinical trials. J. Gerontol. Nurs., 2023, 49(1), 6-10. doi: 10.3928/00989134-20221205-02 PMID: 36594914
Yuksel, J.M.; Noviasky, J.; Britton, S. Aducanumab for Alzheimers disease: Summarized data from emerge, engage, and prime studies. Sr. Care Pharm., 2022, 37(8), 329-334. doi: 10.4140/TCP.n.2022.329 PMID: 35879846
Swanson, C.J.; Zhang, Y.; Dhadda, S.; Wang, J.; Kaplow, J.; Lai, R.Y.K.; Lannfelt, L.; Bradley, H.; Rabe, M.; Koyama, A.; Reyderman, L.; Berry, D.A.; Berry, S.; Gordon, R.; Kramer, L.D.; Cummings, J.L. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimers disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res. Ther., 2021, 13(1), 80. doi: 10.1186/s13195-021-00813-8 PMID: 33865446
Rafii, M.S.; Sperling, R.A.; Donohue, M.C.; Zhou, J.; Roberts, C.; Irizarry, M.C.; Dhadda, S.; Sethuraman, G.; Kramer, L.D.; Swanson, C.J.; Li, D.; Krause, S.; Rissman, R.A.; Walter, S.; Raman, R.; Johnson, K.A.; Aisen, P.S. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimers disease. Alzheimers Dement., 2023, 19(4), 1227-1233. doi: 10.1002/alz.12748 PMID: 35971310
Knopman, D.S. Lecanemab reduces brain amyloid-β and delays cognitive worsening. Cell Rep. Med., 2023, 4(3), 100982. doi: 10.1016/j.xcrm.2023.100982 PMID: 36948153
Piller, C. Report on trial death stokes Alzheimers drug fears. Science, 2023, 380(6641), 122-123. doi: 10.1126/science.adi2242 PMID: 37053319
Asuni, A.A.; Boutajangout, A.; Quartermain, D.; Sigurdsson, E.M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci., 2007, 27(34), 9115-9129. doi: 10.1523/JNEUROSCI.2361-07.2007 PMID: 17715348
Boutajangout, A.; Ingadottir, J.; Davies, P.; Sigurdsson, E.M. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J. Neurochem., 2011, 118(4), 658-667. doi: 10.1111/j.1471-4159.2011.07337.x PMID: 21644996
Yanamandra, K.; Patel, T.K.; Jiang, H.; Schindler, S.; Ulrich, J.D.; Boxer, A.L.; Miller, B.L.; Kerwin, D.R.; Gallardo, G.; Stewart, F.; Finn, M.B.; Cairns, N.J.; Verghese, P.B.; Fogelman, I.; West, T.; Braunstein, J.; Robinson, G.; Keyser, J.; Roh, J.; Knapik, S.S.; Hu, Y.; Holtzman, D.M.; Holtzman, D.M. Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Sci. Transl. Med., 2017, 9(386), eaal2029. doi: 10.1126/scitranslmed.aal2029 PMID: 28424326
Li, L.; Miao, J.; Jiang, Y.; Dai, C.L.; Iqbal, K.; Liu, F.; Chu, D. Passive immunization inhibits tau phosphorylation and improves recognition learning and memory in 3xTg-AD mice. Exp. Neurol., 2023, 362, 114337. doi: 10.1016/j.expneurol.2023.114337 PMID: 36717015
Novak, P.; Schmidt, R.; Kontsekova, E.; Zilka, N.; Kovacech, B.; Skrabana, R.; Vince-Kazmerova, Z.; Katina, S.; Fialova, L.; Prcina, M.; Parrak, V.; Dal-Bianco, P.; Brunner, M.; Staffen, W.; Rainer, M.; Ondrus, M.; Ropele, S.; Smisek, M.; Sivak, R.; Winblad, B.; Novak, M. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimers disease: A randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol., 2017, 16(2), 123-134. doi: 10.1016/S1474-4422(16)30331-3 PMID: 27955995
Novak, P.; Zilka, N.; Zilkova, M.; Kovacech, B.; Skrabana, R.; Ondrus, M.; Fialova, L.; Kontsekova, E.; Otto, M.; Novak, M. AADvac1, an active immunotherapy for Alzheimers disease and non alzheimer tauopathies: An overview of preclinical and clinical development. J. Prev. Alzheimers Dis., 2019, 6(1), 63-69. PMID: 30569088
Hovakimyan, A.; Zagorski, K.; Chailyan, G.; Antonyan, T.; Melikyan, L.; Petrushina, I.; Batt, D.G.; King, O.; Ghazaryan, M.; Donthi, A.; Foose, C.; Petrovsky, N.; Cribbs, D.H.; Agadjanyan, M.G.; Ghochikyan, A. Immunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates. NPJ Vaccines, 2022, 7(1), 117. doi: 10.1038/s41541-022-00544-3 PMID: 36224191
Pagano, G.; Boess, F.G.; Taylor, K.I.; Ricci, B.; Mollenhauer, B.; Poewe, W.; Boulay, A.; Anzures-Cabrera, J.; Vogt, A.; Marchesi, M.; Post, A.; Nikolcheva, T.; Kinney, G.G.; Zago, W.M.; Ness, D.K.; Svoboda, H.; Britschgi, M.; Ostrowitzki, S.; Simuni, T.; Marek, K.; Koller, M.; Sevigny, J.; Doody, R.; Fontoura, P.; Umbricht, D.; Bonni, A. A Phase II study to evaluate the safety and efficacy of prasinezumab in early parkinsons disease (PASADENA): Rationale, design, and baseline data. Front. Neurol., 2021, 12, 705407. doi: 10.3389/fneur.2021.705407 PMID: 34659081
Pagano, G.; Taylor, K.I.; Anzures-Cabrera, J.; Marchesi, M.; Simuni, T.; Marek, K.; Postuma, R.B.; Pavese, N.; Stocchi, F.; Azulay, J.P.; Mollenhauer, B.; López-Manzanares, L.; Russell, D.S.; Boyd, J.T.; Nicholas, A.P.; Luquin, M.R.; Hauser, R.A.; Gasser, T.; Poewe, W.; Ricci, B.; Boulay, A.; Vogt, A.; Boess, F.G.; Dukart, J.; DUrso, G.; Finch, R.; Zanigni, S.; Monnet, A.; Pross, N.; Hahn, A.; Svoboda, H.; Britschgi, M.; Lipsmeier, F.; Volkova-Volkmar, E.; Lindemann, M.; Dziadek, S.; Holiga, .; Rukina, D.; Kustermann, T.; Kerchner, G.A.; Fontoura, P.; Umbricht, D.; Doody, R.; Nikolcheva, T.; Bonni, A. Trial of prasinezumab in early-stage parkinsons disease. N. Engl. J. Med., 2022, 387(5), 421-432. doi: 10.1056/NEJMoa2202867 PMID: 35921451
Kuchimanchi, M.; Monine, M.; Kandadi, M.K.; Woodward, C.; Penner, N.; Phase, I.I. Phase II dose selection for alpha synucleintargeting antibody cinpanemab (BIIB054) based on target protein binding levels in the brain. CPT Pharmacometrics Syst. Pharmacol., 2020, 9(9), 515-522. doi: 10.1002/psp4.12538 PMID: 32613752
Lang, A.E.; Siderowf, A.D.; Macklin, E.A.; Poewe, W.; Brooks, D.J.; Fernandez, H.H.; Rascol, O.; Giladi, N.; Stocchi, F.; Tanner, C.M.; Postuma, R.B.; Simon, D.K.; Tolosa, E.; Mollenhauer, B.; Cedarbaum, J.M.; Fraser, K.; Xiao, J.; Evans, K.C.; Graham, D.L.; Sapir, I.; Inra, J.; Hutchison, R.M.; Yang, M.; Fox, T.; Budd Haeberlein, S.; Dam, T. Trial of cinpanemab in early parkinsons disease. N. Engl. J. Med., 2022, 387(5), 408-420. doi: 10.1056/NEJMoa2203395 PMID: 35921450
Schofield, D.J.; Irving, L.; Calo, L.; Bogstedt, A.; Rees, G.; Nuccitelli, A.; Narwal, R.; Petrone, M.; Roberts, J.; Brown, L.; Cusdin, F.; Dosanjh, B.; Lloyd, C.; Dobson, C.; Gurrell, I.; Fraser, G.; McFarlane, M.; Rockenstein, E.; Spencer, B.; Masliah, E.; Spillantini, M.G.; Tan, K.; Billinton, A.; Vaughan, T.; Chessell, I.; Perkinton, M.S.; Perkinton, M.S. Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo. Neurobiol. Dis., 2019, 132, 104582. doi: 10.1016/j.nbd.2019.104582 PMID: 31445162
Fjord-Larsen, L.; Thougaard, A.; Wegener, K.M.; Christiansen, J.; Larsen, F.; Schrøder-Hansen, L.M.; Kaarde, M.; Ditlevsen, D.K. Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies. MAbs, 2021, 13(1), 1994690. doi: 10.1080/19420862.2021.1994690 PMID: 34709986
Kallab, M.; Herrera-Vaquero, M.; Johannesson, M.; Eriksson, F.; Sigvardson, J.; Poewe, W.; Wenning, G.K.; Nordström, E.; Stefanova, N. Region-specific effects of immunotherapy with antibodies targeting α-synuclein in a transgenic model of synucleinopathy. Front. Neurosci., 2018, 12, 452. doi: 10.3389/fnins.2018.00452 PMID: 30022929
Nordström, E.; Eriksson, F.; Sigvardson, J.; Johannesson, M.; Kasrayan, A.; Jones-Kostalla, M.; Appelkvist, P.; Söderberg, L.; Nygren, P.; Blom, M.; Rachalski, A.; Nordenankar, K.; Zachrisson, O.; Amandius, E.; Osswald, G.; Moge, M.; Ingelsson, M.; Bergström, J.; Lannfelt, L.; Möller, C.; Giorgetti, M.; Fälting, J. ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinsons disease. Neurobiol. Dis., 2021, 161, 105543. doi: 10.1016/j.nbd.2021.105543 PMID: 34737044
Gibbs, E.; Zhao, B.; Roman, A.; Plotkin, S.S.; Peng, X.; Hsueh, S.C.C.; Aina, A.; Wang, J.; Shyu, C.; Yip, C.K.; Nam, S.E.; Kaplan, J.M.; Cashman, N.R. Rational generation of monoclonal antibodies selective for pathogenic forms of alpha-synuclein. Biomedicines, 2022, 10(9), 2168. doi: 10.3390/biomedicines10092168 PMID: 36140270
Valiukas, Z.; Ephraim, R.; Tangalakis, K.; Davidson, M.; Apostolopoulos, V.; Feehan, J. Immunotherapies for Alzheimers disease: A review. Vaccines, 2022, 10(9), 1527. doi: 10.3390/vaccines10091527 PMID: 36146605
Knecht, L.; Folke, J.; Dodel, R.; Ross, J.A.; Albus, A. Alpha-synuclein immunization strategies for synucleinopathies in clinical studies: A biological perspective. Neurotherapeutics, 2022, 19(5), 1489-1502. doi: 10.1007/s13311-022-01288-7 PMID: 36083395
Meissner, W.G.; Traon, A.P.L.; Foubert-Samier, A.; Galabova, G.; Galitzky, M.; Kutzelnigg, A.; Laurens, B.; Lührs, P.; Medori, R.; Péran, P.; Sabatini, U.; Vergnet, S.; Volc, D.; Poewe, W.; Schneeberger, A.; Staffler, G.; Rascol, O.; Anheim, M.; Castrioto, A.; Derkinderen, P.; Drapier, S.; Eusebio, A.; Grabli, D.; Marques, A.; Moreau, C.; Moro, E.; Tranchant, C. A Phase 1 Randomized Trial of Specific Active α-SYNUCLEIN Immunotherapies PD01A and PD03A in Multiple System Atrophy. Mov. Disord., 2020, 35(11), 1957-1965. doi: 10.1002/mds.28218 PMID: 32882100
Yu, H.J.; Thijssen, E.; van Brummelen, E.; van der Plas, J.L.; Radanovic, I.; Moerland, M.; Hsieh, E.; Groeneveld, G.J.; Dodart, J.C. A randomized first-in-human study with UB-312, a UBITh® α-synuclein peptide vaccine. Mov. Disord., 2022, 37(7), 1416-1424. doi: 10.1002/mds.29016 PMID: 35426173
Nimmo, J.T.; Smith, H.; Wang, C.Y.; Teeling, J.L.; Nicoll, J.A.R.; Verma, A.; Dodart, J-C.; Liu, Z.; Lin, F.; Carare, R.O. Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut. Acta Neuropathol., 2022, 143(1), 55-73. doi: 10.1007/s00401-021-02381-5 PMID: 34741635
Schmidhuber, S.; Scheiblhofer, S.; Weiss, R.; Cserepes, M.; Tóvári, J.; Gadermaier, G.; Bezard, E.; De Giorgi, F.; Ichas, F.; Strunk, D.; Mandler, M. A Novel C-type lectin receptor-targeted α-synuclein-based parkinson vaccine induces potent immune responses and therapeutic efficacy in mice. Vaccines, 2022, 10(9), 1432. doi: 10.3390/vaccines10091432 PMID: 36146508
Chen, Z.; Yang, Y.; Yang, X.; Zhou, C.; Li, F.; Lei, P.; Zhong, L.; Jin, X.; Peng, G. Immune effects of optimized DNA vaccine and protective effects in a MPTP model of Parkinsons disease. Neurol. Sci., 2013, 34(9), 1559-1570. doi: 10.1007/s10072-012-1284-6 PMID: 23354599
Petrushina, I.; Hovakimyan, A.; Harahap-Carrillo, I.S.; Davtyan, H.; Antonyan, T.; Chailyan, G.; Kazarian, K.; Antonenko, M.; Jullienne, A.; Hamer, M.M.; Obenaus, A.; King, O.; Zagorski, K.; Blurton-Jones, M.; Cribbs, D.H.; Lander, H.; Ghochikyan, A.; Agadjanyan, M.G. Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials. Neurobiol. Dis., 2020, 139, 104823. doi: 10.1016/j.nbd.2020.104823 PMID: 32119976
Kim, C.; Hovakimyan, A.; Zagorski, K.; Antonyan, T.; Petrushina, I.; Davtyan, H.; Chailyan, G.; Hasselmann, J.; Iba, M.; Adame, A.; Rockenstein, E.; Szabo, M.; Blurton-Jones, M.; Cribbs, D.H.; Ghochikyan, A.; Masliah, E.; Agadjanyan, M.G. Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human α-synuclein: Prelude for IND enabling studies. NPJ Vaccines, 2022, 7(1), 1. doi: 10.1038/s41541-021-00424-2 PMID: 35013319
Masliah, E.; Rockenstein, E.; Mante, M.; Crews, L.; Spencer, B.; Adame, A.; Patrick, C.; Trejo, M.; Ubhi, K.; Rohn, T.T.; Mueller-Steiner, S.; Seubert, P.; Barbour, R.; McConlogue, L.; Buttini, M.; Games, D.; Schenk, D. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One, 2011, 6(4), e19338. doi: 10.1371/journal.pone.0019338 PMID: 21559417
Nimmo, J.T.; Verma, A.; Dodart, J.C.; Wang, C.Y.; Savistchenko, J.; Melki, R.; Carare, R.O.; Nicoll, J.A.R. Novel antibodies detect additional α-synuclein pathology in synucleinopathies: Potential development for immunotherapy. Alzheimers Res. Ther., 2020, 12(1), 159. doi: 10.1186/s13195-020-00727-x PMID: 33256825
Games, D.; Valera, E.; Spencer, B.; Rockenstein, E.; Mante, M.; Adame, A.; Patrick, C.; Ubhi, K.; Nuber, S.; Sacayon, P.; Zago, W.; Seubert, P.; Barbour, R.; Schenk, D.; Masliah, E. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinsons disease-like models. J. Neurosci., 2014, 34(28), 9441-9454. doi: 10.1523/JNEUROSCI.5314-13.2014 PMID: 25009275
Wang, S.; Yu, Y.; Geng, S.; Wang, D.; Zhang, L.; Xie, X.; Wu, B.; Li, C.; Xu, H.; Li, X.; Hu, Y.; Zhang, L.; Kaether, C.; Wang, B. A coimmunization vaccine of Aβ42 ameliorates cognitive deficits without brain inflammation in an Alzheimers disease model. Alzheimers Res. Ther., 2014, 6(3), 26. doi: 10.1186/alzrt256 PMID: 24987466
Xiao, B.; Tan, E.K. Immunotherapy trials in parkinsons disease: Challenges. J. Transl. Med., 2023, 21(1), 178. doi: 10.1186/s12967-023-04012-x PMID: 36879300
Nicoll, J.A.R.; Buckland, G.R.; Harrison, C.H.; Page, A.; Harris, S.; Love, S.; Neal, J.W.; Holmes, C.; Boche, D. Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimers disease. Brain, 2019, 142(7), 2113-2126. doi: 10.1093/brain/awz142 PMID: 31157360
Chu, W.T.; Hall, J.; Gurrala, A.; Becsey, A.; Raman, S.; Okun, M.S.; Flores, C.T.; Giasson, B.I.; Vaillancourt, D.E.; Vedam-Mai, V. Evaluation of an adoptive cellular therapy-based vaccine in a transgenic mouse model of α-synucleinopathy. ACS Chem. Neurosci., 2023, 14(2), 235-245. doi: 10.1021/acschemneuro.2c00539 PMID: 36571847
Olson, K.E.; Namminga, K.L.; Schwab, A.D.; Thurston, M.J.; Lu, Y.; Woods, A.; Lei, L.; Shen, W.; Wang, F.; Joseph, S.B.; Gendelman, H.E.; Mosley, R.L. Neuroprotective activities of long-acting granulocytemacrophage colony-stimulating factor (mpdm608) in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. Neurotherapeutics, 2020, 17(4), 1861-1877. doi: 10.1007/s13311-020-00877-8 PMID: 32638217
Olson, K.E.; Namminga, K.L.; Lu, Y.; Schwab, A.D.; Thurston, M.J.; Abdelmoaty, M.M.; Kumar, V.; Wojtkiewicz, M.; Obaro, H.; Santamaria, P.; Mosley, R.L.; Gendelman, H.E. Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinsons disease. EBioMedicine, 2021, 67, 103380. doi: 10.1016/j.ebiom.2021.103380 PMID: 34000620
Gendelman, H.E.; Zhang, Y.; Santamaria, P.; Olson, K.E.; Schutt, C.R.; Bhatti, D.; Shetty, B.L.D.; Lu, Y.; Estes, K.A.; Standaert, D.G.; Heinrichs-Graham, E.; Larson, L.; Meza, J.L.; Follett, M.; Forsberg, E.; Siuzdak, G.; Wilson, T.W.; Peterson, C.; Mosley, R.L. Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinsons disease trial. NPJ Parkinsons Dis., 2017, 3(1), 10. doi: 10.1038/s41531-017-0013-5 PMID: 28649610
Rohrer, L.; Yunce, M.; Montine, T.J.; Shan, H. Plasma exchange in Alzheimers disease. Transfus. Med. Rev., 2023, 37(1), 10-15.
Boada, M.; López, O.L.; Olazarán, J.; Núñez, L.; Pfeffer, M.; Paricio, M.; Lorites, J.; Piñol-Ripoll, G.; Gámez, J.E.; Anaya, F.; Kiprov, D.; Lima, J.; Grifols, C.; Torres, M.; Costa, M.; Bozzo, J.; Szczepiorkowski, Z.M.; Hendrix, S.; Páez, A. A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimers disease: Primary results of the AMBAR Study. Alzheimers Dement., 2020, 16(10), 1412-1425. doi: 10.1002/alz.12137 PMID: 32715623
Singh, S.; Kumar, K.; Panda, M.; Srivastava, A.; Mishra, A.; Prajapati, V.K. High-throughput virtual screening of small-molecule inhibitors targeting immune cell checkpoints to discover new immunotherapeutics for human diseases. Mol. Divers., 2023, 27(2), 729-751. doi: 10.1007/s11030-022-10452-2 PMID: 35633442
Liu, Y.; Meng, Y.; Zhou, C.; Yan, J.; Guo, C.; Dong, W. Activation of the IL-17/TRAF6/NF-κB pathway is implicated in Aβ-induced neurotoxicity. BMC Neurosci., 2023, 24(1), 14. doi: 10.1186/s12868-023-00782-8 PMID: 36823558
Badr, M.; McFleder, R.L.; Wu, J.; Knorr, S.; Koprich, J.B.; Hünig, T.; Brotchie, J.M.; Volkmann, J.; Lutz, M.B.; Ip, C.W. Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-α-synuclein Parkinsons disease mice. J. Neuroinflammation, 2022, 19(1), 319. doi: 10.1186/s12974-022-02685-7 PMID: 36587195

补充文件

附件文件

动作

1. JATS XML

下载

用户名
密码
记住我

忘记您的密码?	注册

用户名
密码
记住我

忘记您的密码?	注册

Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond

全文:

详细

关键词

作者简介

Jenny Garmendia

Claudia De Sanctis

Viswanath Das

Narendran Annadurai

Marián Hajduch

Juan De Sanctis

参考

补充文件